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ABSTRACT 
 
ABSTRACT 
 
   Prostatism is a common problem in the geriatric age group. Prostatic 
hyperplasia and Carcinoma of the prostate are increasingly frequent with advancing 
age. Prostatic lesions on routine H & E staining, especially when malignant tissue is 
limited and is mixed with benign prostatic glands or due to the presence of benign 
mimickers of carcinoma or technical problems like crush artifact, can cause a 
diagnostic dilemma. Therefore it is not uncommon to under diagnose small focus of 
prostatic adenocarcinoma or over diagnose benign lesions mimicking cancer. In such 
situation, Immunohistochemical detection of basal cells are widely used. The most 
commonly used basal cell specific markers are Cytokeratin 34BetaE12 (High 
molecular weight cytokeratin) and p63. 
Aims:  
The aim of the present study is to study the spectrum of prostatic lesions among 
the biopsies received in a tertiary care hospital in south India and to assess the utility of 
Cytokeratin 34BetaE12 and p63 by Immunohistochemistry in premalignant and 
malignant lesions of prostate.  
Materials and methods:  
A total of 50 prostatic specimens (both retrospective and prospective) received 
in department of pathology over 2 years were evaluated. Routine hematoxylin and eosin 
staining and immunohistochemical staining against CK 34βE12 were performed in 18 
cases (premalignant and malignant lesions.) 
 
Results: 
Among the 50 biopsies received, 78% cases were TURP, 32% cases were 
Trucut needle biopsies.  32 (64%) cases were of Nodular hyperplasia of prostate, one 
case (2%) was Prostatic intraepithelial neoplasia and 17 cases (34%) were Carcinoma 
of Prostate. They were common in the sixth to seventh decade and majority presents 
with urinary symptoms. Pseudo neoplastic lesions like basal cell hyperplasia and 
squamous metaplasia were noted accounts for 32% and 6% respectively. 
Adenocarcinoma diagnosed were graded according to Modified Gleason grading, 
IUSP 2015 guidelines. Gleason grade 2 was seen in 41% cases with score 3+4 = 7. 
Immunohistochemistry was done on 18 cases. p63 is expressed in the nuclei 
of basal cells, whereas 34βE12 stains their cytoplasm. 4 cases showed entrapped 
benign glands. Compared to p63, four cases stained by CK 34βE12 showed 1+ 
staining intensity. This false positive reaction may be because of formalin fixation and 
antigen retrieval.  
Conclusion:  
Benign prostatic hyperplasia is the most commonly encountered prostatic 
lesion. Definitive diagnosis of benign and malignant lesions of prostate can be made 
by histopathological study of prostatic biopsies. Immunohistochemical stains helps in 
confirmation and in cases with diagnostic dilemma. Ultimately, understanding the 
potential pitfalls of IHC stains and paying careful attention to morphologic details are 
crucial to prevent the false-positive and false-negative diagnosis. 
Key Words: 
Prostatic lesions, Gleason’s grading, CK34BetaE12, p63. 
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Prostate is a fibro musculo glandular organ. Enlargement of prostate or growth 
most commonly occurs due to nodular hyperplasia or neoplasm like adenocarcinoma 
and also prostatic intraepithelial neoplasia (PIN), its precursor lesion1. With advancing 
age frequency increases and are uncommon before the age of 40 yrs.2 
Diagnosis of malignancy at higher stage carries poor prognosis hence early 
diagnosis of malignancy is important. More over prostatic cancers are difficult to 
diagnose as these remain asymptomatic for long. With the primary being silent, 
these are notorious for metastasis, particularly to bone.  
Prostatic lesions are routinely diagnosed by biopsies (TURP, needle 
biopsies). Specific histological criteria, like infiltrative small glands, absence of 
basal cell layer and nuclear features can point towards a positive diagnosis of 
carcinoma. Other pathologies like prostatitis, nodular hyperplasia and high grade 
intraepithelial lesions can also be seen.  
Prostatic lesions on routine Haematoxylin & Eosin (H&E) staining 
sometimes cause diagnostic dilemma. Benign lesions, other malignant lesions, 
premalignant lesions like atypical adenomatous hyperplasia (AAH) and prostatic 
intraepithelial neoplasia (PIN) are mimickers of Prostatic carcinoma (PCa) in needle 
biopsies and can be challenging particularly when the malignant tissue is limited and 
is mixed with benign prostatic glands.3 It is not uncommon to underdiagnose a small 
focus of carcinoma or over diagnose benign lesions mimicking cancer. An important 
diagnostic criterion in the differentiation is the loss of basal cell layer in adenocarcinoma 
and its presence in the benign lesions. Several immunohistochemical stains have 
been used to stain the basal cells of prostate, e.g. high molecular weight cytokeratin 
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(CK34BetaE12), p63 etc. To the practicing pathologist, Immunohistology has 
become an integral part of the diagnostic armamentarium.4 
This study is aimed to evaluate a complete spectrum of various prostatic 
lesions in a tertiary care centre in south India during a period of two years and value 
of Immunohistolochemical stains in definite histopathology diagnosis of suspicious 
or atypical prostatic lesions. 
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 To study the Histomorphological spectrum of non-neoplastic and neoplastic 
lesions of prostate in prostatic biopsies. 
 To assess the utility of Cytokeratin 34BetaE12 and p63 by Immuno 
histochemistry in premalignant and malignant lesions of prostate. 
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Prostate is a functional conduit in males that allows urine to pass from 
urinary bladder to the urethra and adds nutritional secretions to the sperms to form 
semen. It surrounds the proximal part of urethra, the prostatic urethra. Knowing the 
normal histology of prostate make us better understand the clinical features and 
pathology of diseases related to prostate. 
ANATOMY 
Prostate is a pear-shaped organ, weighs up to 20 g in normal adults and is 
located within the pelvis. It lies anterior to the rectum, with urethra running through its 
centre and serves as a reference landmark. The base of the prostate is in continuity with 
the bladder and becoming the striated external urethral sphincter ends at the apex.  
Three distinct layers of fascia covers the prostate on the anterior, posterior 
and lateral aspects. The anterior and anterolateral fascia is in direct continuity to the 
true capsule and levator fascia fuses with it laterally. Rectovesical (Denonvilliers) 
fascia covers posteriorly, which is a connective tissue located between the anterior 
wall of the rectum and posterior aspect of the prostate. This fascial layer covers the 
prostate and seminal vesicles posteriorly and extends caudally to terminate as a 
fibrous plate just below the urethra at the level of the external urethral sphincter, 
which is known as the median fibrous raphe. (Fig. 14) The puboprostatic ligament 
supports the gland anteriorly and external urethral sphincter and perineal membrane 
inferiorly. The puboprostatic ligaments are the pubovesical ligament.5 
Prostate is divided into anterior fibromuscular stroma and three distinct 
glandular zones (peripheral zone, transition zone, central zone). Peripheral and 
central zones are included in outer prostate whereas transition zone and anterior 
fibromuscular layer are included in the inner prostate.6 
Review of Literature 
 Page 5 
 
Peripheral zone of the prostate comprises majority of glandular tissue that 
accounts for almost 70%. This zone covers the posterior and lateral aspects of the 
prostate. The peripheral zone is the area that is palpated on digital rectal examination 
(DRE) and this zone represents the area where 70% of adenocarcinomas are found. 
This portion is also most commonly affected by chronic prostatitis.  
The central zone, the area surrounding the ejaculatory ducts consists of 
25% of the glandular tissue. Very few adenocarcinomas are found in this zone, 
which presents with lower urinary tract symptoms. Urethral crest runs along the 
posterior midline and disappears at the membranous urethra. A groove is noted on 
both sides of the urethral crest. Prostatic sinuses exit and drain all the glandular 
elements in this area. 
The transition zone accounts for 10% of the prostatic glandular tissue and 
20% of the adenocarcinomas in this region and this zone represent only 1-5% of 
tumors in the prostate.5, 7 
The arterial supply to the prostate is from the inferior vesical artery, a branch 
of anterior division of the internal iliac (hypogastric) artery and then it branches into 
two main arteries that supply the prostate. This also supplies the base of the bladder 
and the distal ureters. The prostatic vessels and the autonomic innervations run 
between the layers of the lateral prostatic fascia and the prostate.  
The venous drainage starts with the deep dorsal vein, which leaves the penis 
under the deep penile (Buck) fascia between the corpora cavernosa and then under 
the pubic arch. One of the common sites for metastasis of prostatic cancer is 
vertebral column that occurs as a result of tumor spread via venous plexuses. 
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The lymphatic drainage of the prostate primarily drains to the obturator and 
the internal iliac lymphatic channels. There is also lymphatic communication with 
the external iliac, presacral, and para-aortic lymph nodes.  
Parasympathetic, visceral, efferent and preganglionic fibres form the 
autonomic innervations of the prostate, arises from the pelvic plexuses. 
Preganglionic fibres arise from the sacral levels (S2-S4) and the sympathetic fibres 
from the thoracolumbar levels (L1-L2). The parasympathetic nerves ends at the acini 
and leads to prostatic secretion. The sympathetic nerves are responsible for 
contraction of the smooth muscle on the capsule and the stroma.  
NORMAL HISTOLOGY 
Prostate is made up of duct and acini arranged in a complex pattern which is 
embedded in a dense fibro muscular stroma. The glands show irregular contour with 
luminal undulation and papillary infolding and are lined by double layered 
epithelium, luminal secretory cells and peripheral basal cells. Prostate glands of 
central zone are morphologically distinct from peripheral and transition zones 
glands. Peripheral zone and transition zone are composed of small simple acini in 
lobular configuration with loose and dense stroma respectively. The cells lining the 
acini shows clear cytoplasm. Central zone is composed of large complex acini with 
cribriform and intraluminal ridges with eosinophilic cytoplasm of the lining cells. A 
layer of flattened cell is seen at the base called as the basal layer. The lumen 
contains small luminal secretions, sometimes forms spherical concretions, the 
corpora amylacea. (Fig. 15) The supporting stroma is a mixture of collagenous 
fibrous tissue and smooth muscle fibers.8 
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PSA Estimation 
In 1979, Wang9 and associates isolated prostate-specific antigen, Prostate-
specific antigen (PSA) is also known as gamma-semino protein or kallikrein-3 
(KLK3), a glycoprotein of 34,000 Daltons encoded in humans by the KLK3 gene. 
Epithelial cells of the prostate gland secrete PSA, a member of the Kallikrein-related 
peptidase family. PSA is produced for the ejaculate, where it liquefies semen in the 
seminal coagulum and allows sperm to swim freely.10 
Methods such as Western blot or enzyme-linked immunosorbent assay 
(ELISA) detect specific protein via fluorescence or other chemically-induced signals 
which is used for quantification of PSA. Although highly specific for tissue of 
prostatic origin, PSA is not cancer-specific as serum PSA levels are commonly 
elevated in benign conditions like prostatitis, benign nodular hyperplasia, infarct and 
major trauma such as needle biopsy and transurethral resections. In contemporary 
series, where most men undergo needle biopsy for PSA >4.0ng⁄ml, fewer than half 
of biopsies result in a diagnosis of prostate cancer.  
PSA density - calculated by dividing the total serum PSA level by the estimated 
gland volume to estimate the PSA produced per gram of prostate tissue. 
PSA velocity - Rapidity of change in PSA level is measured by PSA velocity and a 
value more than 75ng/ml/year should trigger a biopsy referral. At least three PSA 
measurements must be performed over a period of 1.5 to 2 years.11 
Ratio of free and bound PSA in the serum – Immunoreactive PSA exists in two 
forms: major fraction bound to Alpha 1-antichymotrypsin and minor free fraction. 
Percentage of free PSA (free PSA/total PSA × 100) is lower in men with prostate 
cancer than in men with benign prostatic diseases. 
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Age-specific PSA 
› 2.5 ng/mL for men 40 to 49 years  
› 3.5 ng/mL for men 50 to 59 years 
› 4.5 ng/mL for men 60 to 69 years 
› 6.5 ng/mL for men 70 to 79 years 
Prostatic cancer gene 3 assay: It is a noncoding RNA which is overexpressed in 
95% of prostate cancers. Elevated urine PCA3 scores have been shown to be 
associated with an increased risk of a positive biopsy 
PROSTATIC BIOPSY12 
Specimens received include prostatic needle biopsies, Trans Urethral 
Resection of Prostate (TURP), rarely radical and suprapubic prostatectomy. 
Prostatic needle biopsy 
Prostatic needle biopsy is usually done as an outpatient procedure. Biopsy is 
done by the urologist in patients suspected of prostatic pathology mostly carcinoma 
and with hard prostate on digital rectal examination, rarely for prostatitis.  
Majority agree that TRUS guided prostate needle biopsy should be 
performed in men with an abnormal Digital Rectal Examination (DRE), an elevated 
PSA (>4.0 ng/ml) or PSA velocity (rate of PSA change) >0.4 to 0.75ng/ml/yr. Also, 
repeat biopsy after 3 to 12 months has to be done for men who were diagnosed with 
high-grade prostatic intraepithelial neoplasia (PIN) or atypia on a previous prostate 
needle biopsy.13 
An 18-gauge biopsy needle loaded in a spring-action automatic biopsy 
device is commonly used to procure multiple 1.5cm prostate biopsy specimens. It is 
Review of Literature 
 Page 9 
 
done under local infiltration. Hard nodules in prostatic areas are sampled using 
prostatic biopsy “gun” needles after per rectal examination. 
In transrectal ultrasound, hypoechoic lesion (dark compared to normal tissue) 
in the peripheral zone is the most common appearance for cancer. With PSA based 
screening and earlier cancer detection, fewer overt abnormal sonographic findings 
are being detected at the time of transrectal ultrasound.14 Systematic sextant TRUS-
guided prostate biopsies have traditionally been done with no form of anaesthesia 
and have been relatively well tolerated. Sextant biopsies from six different sites are 
sampled and labelled separately. Hodge et al. in 1989, directed the biopsies to 6 
standard quadrants and also to hypoechogenic areas (Bx6C). This standard 
procedure identified PCa in 62% of 136 patients.13 
Biopsies obtained using a “biopsy gun,” are usually thin and are processed as 
single core in individual cassettes. To detect significant lesions, three levels are 
needed. Additional levels may show PCa if focal glandular atypia is found in the 
first three slides.  
TURP 
TURP is usually carried out using a device called a resectoscope. It is a thin 
metal tube containing a light, camera and loop of wire. Resectoscope is inserted by 
the surgeon into the urethra before guiding it to the site of prostate with the help of 
the light and the camera. A catheter is used to pump fluid into the bladder after the 
procedure and this flushes away pieces of prostate that have been removed. (Fig. 16) 
Multiple fragments are curetted from the central and transitional zone of the 
prostate in order to relieve obstruction. Carcinoma may be found in 7% to 8% of 
TURPs with limited sampling and 14% to 19% if the entire specimen is examined.  
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CAP15 (College of American Pathologist) recommends examining of entire 
specimen if weighing 12 grams or less. For larger specimens, the first 12 grams 
should be submitted (in 6 to 8 cassettes – in general 1 to 2 grams of tissue will fit in 
one cassette), with one more cassette for each additional 5 grams of tissue. The 
remaining tissue is generally submitted for examination if an unsuspected carcinoma 
is found involving <5% of tissue. If any firm, yellow or yellow-orange chips are 
present, they should be submitted, as these chips are more likely to contain 
carcinoma.  
Additional recommendations in the literature have been mentioned to submit 
the entire specimen in the following situations includes patients <60 years of age 
(small low grade carcinomas may be more likely to become clinically significant in 
this group) and patients with elevated PSA.  
Suprapubic Prostatectomy 
Enucleation procedures are rare and performed when the prostate is much 
enlarged or if there are other contraindications (e.g., urethral disease, bladder 
diverticula) for transurethral surgery. The specimen usually looks like a large apple 
with a wedge cut out of one side, but may come in two or more fragments. There are 
usually no orienting features. Margins are irrelevant since the entire prostate is not 
removed. Serial sections to be made at 3 to 4 mm thickness. The parenchyma 
including color (white/tan, yellow, gray), consistency (firm, hard, soft, indurated), 
areas of necrosis or hemorrhage. Carcinomas may be more yellow and firmer than 
hyperplastic nodules. Submit at least eight cassettes from different areas including 
right and left lobes, urethra (if recognizable), capsule and any areas suspicious for 
tumor. 
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Radical Prostatectomy 
Radical prostatectomies are not performed in the present era. Numerous 
protocols for submitting tissue have been proposed ranging from submission of the 
entire specimen in whole mount specimens to limited sampling using standard 
slides. Any method used should be designed to evaluate the extent of carcinoma, 
grade, stage and margin status. 
Prostatic biopsies obtained are fixed in 10% formalin, paraffin embedded 
and stained with Haematoxylin and Eosin (H&E) routinely for assessment of 
malignancy or other pathology. 
COMPLICATIONS OF BIOPSY 
Persistent haematuria is the most common complication. Intraoperative 
complications can also occur including vasovagal episodes. Hematochezia (rectal 
bleeding) and hematospermia (blood in the semen) are other alarming symptoms 
that can occur, although most subside spontaneously. 
According to International Society of Urologic Pathology (ISUP) 2005 
guidelines, Malignancy when detected should be graded according to Modified 
Gleason score. Review of a few common and benign conditions of prostate are 
elaborated below, before a discussion of carcinoma. 
NONNEOPLASTIC LESIONS OF THE PROSTATE 
Prostatitis: 
Prostatitis occurs in approximately 10% to 15% of men. The term prostatitis 
refers to microscopic inflammation of the tissue of the prostate gland. It can be 
bacterial induced or not.16 Prostatitis is classified into 4 categories: acute bacterial 
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(National Institutes of Health [NIH] type I); chronic bacterial (NIH type II); chronic 
prostatitis/chronic pelvic pain syndrome (NIH type III), which is divided into 
inflammatory (type IIIA) and noninflammatory (type IIIB); and finally, 
asymptomatic (NIH type IV). Asymptomatic prostatitis or NIH type IV is the most 
common type of prostatitis encountered by the surgical pathologist.17 Most have 
chronic inflammation (94%) followed by acute inflammation (6%), and rarely, 
granulomatous inflammation (0.2%). Studies describing inflammation in the prostate 
have subclassified it by the type of inflammatory cell, location and pattern of 
inflammation (glandular, stromal and periglandular) and extent or grade.18 
Acute prostatitis: 
Acute prostatitis is due to the inflammation produced by bacteria with the 
common etiological agent being gram negative organisms. The organisms become 
implanted in the prostate by intraprostatic reflux of urine from the posterior urethra 
or urinary bladder, but occasionally from distant foci of infection they seed the 
prostate by lympho haematogenous routes. Acute prostatitis may appear as minute, 
disseminated abscesses (Fig.17) to large, coalescent focal areas of necrosis.19 
Chronic Prostatitis: 
Chronic bacterial prostatitis the presentation is that of recurrent urinary tract 
infection. Bacteria find safe in the parenchyma and constantly seed the urinary tract 
since antibiotics do not penetrate the prostatic stroma. Pathogenesis of chronic 
prostatitis involves reflux of infected urine into prostatic ducts, with associated 
factors contributing to infection such as infected prostatic calculi and local prostatic 
duct obstruction. 
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Granulomatous prostatitis: 
Granulomatous inflammation can be seen in the prostate but is less common. 
Mainly consists of nonspecific granulomatous prostatitis and is characterized by 
granulomatous inflammation arranged concentrically around prostatic ducts or 
glands and can be accompanied by giant cells and a mixture of inflammatory cells.20 
The most common cause in the west is related to instillation of BCG within the 
bladder for treatment of superficial bladder cancer.21(Fig.18) 
Xanthogranulomatous Prostatitis: 
As the name indicates it is nothing but collections of lipid-laden macrophages 
in the prostate. Xanthomatous histiocytes have small uniform nuclei with 
inconspicuous nucleoli and are commonly admixed with other types of inflammatory 
cells.22 Multiple inflammatory cytokines have been identified as potential mediators in 
interplay between prostatic inflammation and prostate carcinogenesis. Macrophage 
inhibitory cytokine 1 (MIC-1), a member of the transforming growth factor-β (TGF-β) 
family is one of the cytokine. In prostate cancer, multiple lines of evidence point to a 
contributory role of IL-6 in cancer initiation and ⁄ or progression. Regions of prostatic 
atrophy, which are generally associated with inflammation, referred to as 
proliferative inflammatory atrophy (PIA), contain atrophic epithelial cells that 
appear to be regenerating in response to cellular damage. Wang et al. also 
documented the morphological transition between PIA and PIN as well as PIA and 
prostate cancer.23 
Nodular Hyperplasia of Prostate 
Most common disease diagnosed in prostate and affects elderly men. 
Prevalence increases with age.  Microscopic evidence of hyperplasia is seen in 90% 
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of men above 80 years, only 50% develop clinically detectable prostatic enlargement 
out of which only 50% develop symptoms.24 Patients may experience symptoms like 
increased urinary frequency, nocturia, difficulty in starting and stopping the stream 
of urine, overflow dribbling and dysuria.  
Microscopy is characterized by nodular proliferation. The composition of the 
nodules may be purely stromal (fibrous), fibromuscular, muscular, 
fibroadenomatous and fibromyoadenomatous. Glandular proliferation takes the form 
of aggregations of small, large to cystically dilated glands, lined by two layers, an 
inner columnar and an outer cuboidal or flattened epithelium. (Fig.19) The histology 
of glandular or mixed glandular-stromal nodules cannot be appreciated in limited 
samples hence diagnosis of nodular hyperplasia cannot be made on needle biopsy. 
Drawback of transrectal needle biopsies is that, it do not typically sample the 
periurethral transition zone where nodular hyperplasia commonly occurs. 25 
Diagnosis of nodular hyperplasia from needle core biopsies of the prostate is 
discouraged, since no correlation was found between the histologic findings on 
needle core biopsy and clinical or symptomatic nodular hyperplasia. Stromal 
nodules can be confidently identified on needle core biopsies; however, they are not 
unique to nodular hyperplasia of prostate, since they have been identified in small-
sized prostates (15.0 g)26  
PSEUDO NEOPLASTIC LESIONS OF PROSTATE 
The diagnosis of prostatic adenocarcinoma, especially when present in small 
amounts, is often challenging. Before making a diagnosis of carcinoma, pathologist 
must consider the various benign patterns and processes that can simulate prostatic 
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adenocarcinoma. Most of these lesions are readily recognized and easily separated 
from malignancy but can become problematic when dealing with limited sampling 
especially in thin core needle biopsies. Most benign mimickers enter the differential 
diagnosis of small acinar adenocarcinoma which is the predominant pattern of 
adenocarcinoma that corresponds to Gleason patterns 1, 2 and 3. Awareness of the 
differential diagnosis of prostatic adenocarcinoma is especially important in the 
context of diagnosing limited carcinoma in small biopsy samples.27,28  
Seminal vesicle 
Seminal vesicle tissue may be present in needle biopsies or in transurethral 
resectates usually unexpectedly. Microscopically it shows central lumen with 
branching glands surrounded by smooth muscle. End branching is complex with 
numerous small glands, resulting in the so-called adenotic pattern of seminal vesicle. 
When the overall gland structure and central lumen are not recognized this latter 
pattern can present problems. Presence of pleomorphism and nuclear 
hyperchromasia which at times striking is helpful in differentiating adenotic seminal 
vesicle from carcinoma.29,30  
Cowper's gland 
Bulbourethral glands also referred to as Cowper's glands, are paired 
periurethral structures located near the prostatic apex. They are rarely sampled in 
prostatic specimens. Cowper's glands have a lobular configuration with tightly 
packed round acini composed surrounding a central duct. Small acinar carcinoma is 
rarely confused with these glands. The duct-acinar architecture, lack of cellular 
atypia and cytoplasmic mucin distinguish adenocarcinoma from Cowper's glands.31 
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Atrophy 
Older patients have atrophied prostatic glands but not exclusively. Atrophy is 
also seen in young adult prostate and is commonly admixed with areas of nodular 
prostatic hyperplasia.32 It is also seen in the central and transition zones eventhough 
common in the peripheral zones. Glandular atrophy is commonly associated with 
chronic prostatitis which may have an active component characterized by 
intraglandular neutrophils. Diagnosis may be particularly challenging and one 
should be cautious in diagnosing carcinoma in inflamed small gland foci when 
atrophy is associated with inflammation, especially active inflammation. Stromal 
fibrosis may be seen in association with radiation therapy and use of antiandrogens, 
which result in architectural distortion. When coupled with radiation effects like 
cytological atypia can cause considerable diagnostic confusion.  
Four main patterns of atrophy are recognized that includes sclerotic, cystic, 
lobular (simple) and linear or streaming. Combined patterns are common. 
Occasionally, atrophy may have a linear, streaming pattern in which small dark acini 
are lined up in a row permeating through stroma. This pattern is prone to be 
overinterpreted as carcinoma.33 
Cells are small, dark and shrunken, have high nuclear to cytoplasmic ratio 
but the nuclei are uniform and lack nuclear membrane irregularity and chromatin 
abnormalities. Maintenance of lobular architecture in low power at least in part, 
uniform cytology and absence of prominent nucleoli differentiates small acinar 
adenocarcinoma. Double layering of cells is mostly seen but in some conditions 
because of the marked secretory cell atrophy it may be difficult to appreciate. In 
such cases, stains highlighting the basal cell compartment may be employed.34 
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Post-atrophic hyperplasia 
2–3% of prostatic needle biopsy cases show post-atrophic hyperplasia, an 
uncommon histological process. Also referred to as partial atrophy or hyperplastic 
atrophy and is usually found in the peripheral zone. But it is difficult to know if 
post-atrophic hyperplasia represents a normal or hyperplastic focus undergoing 
atrophy (partial atrophy) or secondary hyperplasia occurring in atrophic areas. Post-
atrophic hyperplasia consists of a combination of atrophic acini and contain more 
abundant clear or amphophilic cytoplasm and appear hyperplastic. This architecture 
of post-atrophic hyperplasia may cause diagnostic confusion with adenocarcinoma. 
However some degree of lobular architecture and basal cells are generally 
maintained and are usually recognized even at the H&E level.  
The prudent use of immunostains is important. There is a discontinuous layer of 
basal cells in post-atrophic hyperplasia whereas the basal cell layer is completely absent 
in small acinar carcinoma. Luminal crystalloids and even small amounts of basophilic 
luminal mucus may be present in post-atrophic hyperplasia in rare instances.35,36  
Reactive atypia 
Glands in acute or chronic prostatitis can exhibit epithelial atypia and may 
sometimes be present in association with prostatic ischemia (infarction). Reactive atypia 
can be confused with adenocarcinoma. The glands are atrophic in most cases of reactive 
atypia and there may be some associated basal cell or transitional cell hyperplasia.37  
Nephrogenic metaplasia 
Nephrogenic metaplasia (adenoma) is uncommonly encountered in the 
subjacent prostatic tissue and prostatic urethra. This may be present as flat or nodular 
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abnormality or an exophytic (papillary) lesion. Nephrogenic metaplasia displays 
exophytic papillary and tubulocystic elements. Nephrogenic metaplasia shows small 
acini with scanty cytoplasm. Small size of the acini, cystic dilatation and inflamed 
stroma separates nephrogenic metaplasia from small acinar carcinoma. Immunostains 
may be helpful sometimes but not all cases of nephrogenic metaplasia.38 
Squamous metaplasia 
Squamous metaplasia is usually seen at the periphery of infarcts, after 
transurethral resection, hormonal manipulation, or sometimes without any 
predisposing cause.39 (Fig. 20) 
Basal cell hyperplasia 
Basal cell hyperplasia is typically seen as a part of the continuum of nodular 
hyperplasia in samples from the transition zone of prostate. In recent times researches 
say that basal cell hyperplasia may also affect the peripheral zone. It is identified in 
transurethral resection specimens but may be encountered in needle biopsies as well. 
Basal cell hyperplasia may also occur in association with atrophy and frequently in the 
setting of antiandrogen therapy. Microscopically characterized by uniform round 
glands with nodular expansion and associated cellular stroma. (Fig.21) It may be 
complete or incomplete.  
Basal cell hyperplasia may be confused with adenocarcinoma. The nodular 
arrangement, association with ordinary nodular hyperplasia, cellular uniformity and 
lack of prominent nucleoli serves to separate this condition from cancer. The 
distinction relies on the recognition of uniform cytological and nuclear features and 
in some instances may require immunohistochemical staining.40 
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Sclerosing adenosis 
Young and Clement in 1987 first used the term sclerosing adenosis of 
prostate to describe an infrequent prostatic proliferative lesion which look like 
sclerosing adenosis of breast.41 
Sclerosing adenosis though uncommon, it is largely restricted to the 
transition zone but generally found in transurethral resectates or radical 
prostatectomy specimens. This condition is described as a vaguely circumscribed 
proliferation of variably sized small glands surrounded by a cellular and often 
edematous stroma. Recognized sometimes on low power as a lightly basophilic 
stroma. Tiny microacini, cords, solid clusters and single cells are seen. A double 
layer is present but may be difficult to appreciate with the H&E stain.42 
Verumontanum mucosal gland hyperplasia 
Verumontanum mucosal gland hyperplasia is identified as an incidental 
finding with one or more foci of hyperplastic verumontanum mucosal glands. This 
feature is rarely encountered in needle biopsy specimens. Microscopy reveals 
closely packed relatively uniform round glands containing numerous corpora 
amylacea. Basal cells are usually identified and there is a lack of nuclear features of 
malignancy. Acinar pattern, cellular uniformity, basal cells and prominent corpora 
amylacea are features suggesting hyperplasia over low grade adenocarcinoma.43 
Hyperplasia of mesonephric glands 
Mesonephric gland remnants are not often identified in prostatic specimens. 
0.6% of mesonephric remnants were identified in a series of close to 700 
transurethral resectates. Hyperplasia in mesonephric gland remnants may be 
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mistaken for adenocarcinoma. The hyperplastic mesonephric glands have an 
infiltrative appearance and are small. Epithelial tufting, tubular dilatation and 
micropapillary formations are also seen. They may demonstrate extra prostatic 
extension and perineural spread, both features are seen in carcinoma. Dense 
eosinophilic luminal substance in small glands contrast with the loose granular 
eosinophilic material typical of small acinar carcinoma. Immunohistochemistry for 
identifying basal cells may be helpful in difficult cases.44 
Clear cell cribriform hyperplasia 
Areas of prominent cribriform glands are occasionally displayed in benign 
nodular hyperplasia and rarely the histologic picture is dominated by this cribriform 
process. Crowded proliferation of complex glands and lack of cytological atypia is 
characteristic of cribriform hyperplasia. The cells in the central area are cuboidal to 
low columnar secretory-type cells with clear cytoplasm, uniform round nuclei without 
nuclear atypia and nucleolar enlargement. Periphery shows prominent basal cell layer. 
Due to its peculiar architecture, both prostatic intraepithelial neoplasia and cribriform 
adenocarcinoma enters the differential diagnosis of cribriform hyperplasia. Low 
power nodularity, presence of basal cells, cellular stroma and lack of significant 
cytologic atypia separates cribriform hyperplasia from cribriform carcinoma.45 
Paraganglion 
Prostatic and periprostatic tissue show paraganglionic tissue may be 
encountered within, usually in the latter. Paraganglia are small, solid nests of cells 
often with a 'zellballen' arrangement and cytoplasm is amphophilic or clear. 
Background shows delicate network of capillaries. The nuclei appears 
hyperchromatic but nucleoli and other features of adenocarcinoma are not seen. 
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Fibrous stroma separates the islands of paraganglionic tissue. Paraganglionic tissue 
can mimic the fused gland pattern of adenocarcinoma Gleason score-4.46 
Degenerative changes in lymphocytes and stromal cells 
Signet ring-like morphology can occur when lymphocytes and sometimes 
stromal cells undergo degenerative changes. When such change is prominent, it can 
resemble high-grade adenocarcinoma composed of individual signet ring cells. The 
artifactual signet ring-like pattern initially described in transurethral resectates, may 
be found in needle biopsies.47 
PREMALIGNANT LESIONS OF PROSTATE 
Premalignant lesions of the prostate include Prostatic intraepithelial 
neoplasia (PIN), particularly high-grade PIN (HGPIN) and atypical small acinar 
proliferation (ASAP). PIN refers to the precancerous end of a morphologic spectrum 
involving cellular proliferation within prostatic acini, ductules and ducts. ASAP and 
HGPIN should not be used interchangeably, these two categories differ from each 
other. Neither ASAP nor HGPIN can metastasize. The enlargement of prostate 
occurs due to nodular prostatic hyperplasia but this is unrelated to HGPIN. Areas in 
the prostate may have palpable nodules or other areas may indicate cancer. None of 
these physical findings suggests the presence of HGPIN or ASAP. 
Prostatic Intraepithelial Neoplasia 
Bostwick and Brawer in 1987 introduced the term PIN. Prostatic 
Intraepithelial Neoplasia, commonly referred to as PIN is an abnormal proliferation 
within the prostatic ducts, ductules, and large acini of premalignant foci of cellular 
dysplasia and carcinoma in situ without stromal invasion.48,49 
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An autopsy study from older men of step-sectioned whole mount prostates 
showed that the prevalence of PIN in prostates with cancer, increased with age 
predating the onset of carcinoma by more than five years.50 
PIN is characterized by cellular proliferation within pre-existing ducts and 
acini with cytologic changes including nuclear and nucleolar enlargement mimickes 
cancer. (Fig.22) Depending on the characteristics like cell crowding, pleomorphism, 
stratification, nuclear enlargement, nucleolar appearance and chromatin pattern 
initially it was divided into three grades. These are graded into the low grade PIN 
(corresponding to grade 1 and 2) and high grade PIN (corresponding to grade 3). 
Low grade PIN is a common finding in young male patients. Its association 
with adenocarcinoma has been questioned and was recently removed from World 
Health Organization (WHO) classification. Four main patterns of high-grade PIN are 
tufting, cribriform, micropapillary and flat. Although most cases have multiple 
patterns, tufting pattern is the most common and is  present in 97% of cases.39 In an 
analysis of 17 studies, in which a total of 87,713 patients underwent biopsy, 3735 
(4.26%) patients had HGPIN. The largest contributors to this study were Orozco et al, 
with 62,537 patients (of whom 4.1% had HGPIN), and Novis et al, with 15,753 
patients (of whom 3.9% had HGPIN).51, 52 
Basal cell–specific monoclonal antibodies targeted against high–molecular 
weight keratin is used to identify HGPIN cells. Normal prostatic epithelial cells 
stained consistently with these antibodies, exhibiting an intact, continuous, 
circumferential basal cell layer. Receptors for these antibodies are lost in cancer 
cells. Basal cell disruption affects 56% of patients with HGPIN and is usually found 
in glands adjacent to invasive cancer. HGPIN correlates with the degree of 
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disruption. More than one third of the basal cell layer is lost in 52% of foci that 
contain HGPIN.  Similar genetic alterations include loss of heterozygosity (LOH) at 
8p22, 10q11.2 and gain of chromosomes 7, 8, 10, and 12 are seen in both High-
grade PIN and prostate cancer. Modifications in oncogene Bcl2 expression and 
RER+ phenotype were similar for PIN and prostate cancer.53 
Atypical small acinar proliferation (ASAP) 
The category ASAP includes a group of lesions (Adenosis, intraductal 
hyperplasia, atypical adenomatous hyperplasia, and acinar atypical hyperplasia) that 
have unpredictable clinical significance. Some ASAP lesions mimic cancer, and in 
many occasions, focal carcinoma may be present, but architectural atypia, 
cytological and histochemical features are insufficient to establish a definitive 
diagnosis of cancer.  
Borboroglu et al., in their study reported detection rates of cancer on repeat 
biopsy was ranging from 25-79% for HGPIN and 21-51% for ASAP.54  
Moore et al., evaluated the biopsy results of 105 men to further evaluate a 
finding of HGPIN or ASAP, repeat extended biopsies were performed and found that 
repeat biopsy revealed cancer more often in patients with ASAP than in those with 
HGPIN. In the HGPIN group, based on first repeat biopsy results, cancer was 
diagnosed in 1 (4.5%) of 22 men and in 0 of 11 based on a second repeat biopsy 
result. The results in the ASAP group were much different. 19 (36%) of 53 men in 
their first repeat biopsy revealed cancer and 13 (16%) of 19 on a second repeat 
biopsy.55 
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When HGPIN and ASAP is identified, as these entities are often found in 
prostates in which prostate cancer cells are present, Pathologist should carefully hunt 
tissue specimens for evidence of cancer. Indeed, it was because of this association that 
these lesions came to be considered noncancerous precursors to the development of 
actual prostate cancer. A follow-up protocol is usually initiated if no cancer cells are 
identified in the patient, since there is a higher risk of prostate cancer in these 
individuals. The follow-up protocol consists of physical examination, serum PSA 
estimation and possibly repeat biopsies. However, the presence of a small amount of 
HGPIN in only 1-2 cores is considered to be insignificant and these patients require no 
special follow-up. ASAP represents a potentially more serious situation. The finding 
of ASAP in even a single biopsy sample requires a follow-up biopsy at 6 months. 
Urologist has to initiate therapy with repeated findings of ASAP.56 
WHO CLASSIFICATION OF TUMORS OF THE PROSTATE- 2016.57 
Epithelial tumors 
Glandular neoplasms 
 Acinar adenocarcinoma 
o Atrophic 
o Micro cystic 
o Foamy gland 
o Signet ring-like cell 
o Clear cell adenocarcinoma 
o Pleomorphic giant cell 
o Sarcomatoid 
 Prostatic intraepithelial neoplasia, high-grade 
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 lntraductal carcinoma 
 Ductal adenocarcinoma 
o Cribriform 
o Papillary 
o Solid 
 Urothelial carcinoma 
Squamous neoplasms 
 Adenosquamous carcinoma 
 Squamous cell carcinoma 
Basal cell carcinoma 
Neuroendocrine Tumors 
 Adenocarcinoma with neuroendocrine differentiation 
 Well differentiated neuroendocrine tumor 
 Small cell neuroendocrine carcinoma 
 Large cell neuroendocrine carcinoma 
Mesenchymal Tumors 
 Stromal tumor of uncertain malignant potential 
 Stromal sarcoma 
 Leiomyosarcoma 
 Rhabdomyosrcomaa 
 Leiomyoma 
 Angiosarcoma 
 Synovial sarcoma 
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 Inflammatory myofibroblastic tumor 
 Osteosarcoma 
 Undifferentiated pleomorphic sarcoma 
 Solitary fibrous tumor 
 Solitary fibrous tumor, malignant 
 Haemangioma 
 Granular cell tumor 
Haematolymphoid tumors 
 Diffuse large B-cell lymphoma 
 Chronic lymphocytic lymphoma/ small lymphocytic lymphoma 
 Follicular lymphoma 
 Mantle cell lymphoma 
 Acute myeloid leukaemia 
 B lymphoblastic leukaemia/ lymphoma 
Miscellaneous tumors 
 Cystadenoma 
 Nephroblastoma 
 Rhabdoid tumor 
 Germ cell tumors 
 Clear cell adeno carcinoma 
 Melanoma 
 Paraganglioma 
 Neuroblastoma 
Metastatic tumors 
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CARCINOMA PROSTATE 
Among men in the United States, Carcinoma of prostate is the most common 
internal malignancy and is responsible for 10% of cancer related death in men.39 It 
constitutes about 5% of all male cancers in India. The prevalence of pathologic 
prostate cancer is extremely high and increases with age. In autopsy series 
pathologic prostate cancer is seen in men in their 20s and 30s and increases to more 
than 80% over the age of 70.58 
The vast majority of prostatic cancers was acinar adenocarcinomas. 
Histological variants of PCa have been variably defined. One approach is to 
consider two groups of variants. Histological variants of acinar adenocarcinoma 
were included in the first group and the second group comprises the non-acinar 
carcinoma variants or types. Variants of usual acinar adenocarcinoma defined in 
2016 by the WHO include pseudo hyperplastic, atrophic, foamy, signet ring 
(Fig.23), oncocytic, colloid and lymphoepithelioma-like carcinomas. Other types of 
Pca that originate in the prostate includes ductal adenocarcinoma, sarcomatoid 
carcinoma, squamous and adenosquamous carcinoma, basal cell carcinoma, 
urothelial carcinoma and neuroendocrine tumors, particularly small-cell carcinoma 
accounts for about 5–10% of carcinomas.57,59,60 
Morphology 
Diagnosis of PCa requires a synthesis of a group of histological attributes 
that allows for a definitive diagnosis. Epstien J I61 in his review has observed that 
infiltrative small and crowded glands favors malignancy. Scattered neoplastic glands 
infiltrate widely between larger benign glands at the edge of most adenocarcinomas. 
One first has to identify the normal non-neoplastic prostate and then search for 
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glands that do not fit morphologically in order to identify limited amounts of cancer 
on needle biopsy material. At low power magnification presence of a focus of 
crowded glands raises a suspicion of carcinoma.  
The second architectural pattern that is suspicious for adenocarcinoma of 
the prostate is the presence of small glands situated between larger benign glands. 
Benign glands are identified by their large size, branching and papillary in folding. 
The presence of small neoplastic glands situated in between benign glands is a 
manifestation of their infiltrative nature. When small atypical glands are seen on 
both sides of a benign gland it is even more diagnostic of malignancy. 
Cytologically hyperchromasia, prominent nucleoli with enlargement and mitotic 
figures are in favour of malignancy(Fig.24). Sharp luminal borders with 
amphophilic cytoplasm are seen in malignancy whereas normal acini have pale to 
clear cytoplasm.  
Prostatic intraluminal crystalloids (Fig.25) that appear in various geometric 
shapes such as hexagonal, triangular, rectangular and rod-like structures are dense 
eosinophilic crystal-like structures and seen in malignant acini in 25% of cases.  
Acini of prostatic adenocarcinoma have acidic sulfated and non-sulfated 
mucin in up to 52% of cases, that appears as amorphous or delicate thread-like 
faintly basophilic secretions in routine H&E sections.61, 62 
Bostwicket et al., describes collagenous micronodules (mucinous fibroplasia) 
as specific but incidental and infrequent finding in prostatic adenocarcinoma. These 
are of microscopic nodular masses of paucicellular eosinophilic fibrillar stroma that 
impinge on lumen of the acini seen in mucin-producing adenocarcinoma and is due 
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to extravasation of acidic mucin into the stroma.63 Glomerulations a sign of 
malignancy, consist of glands with a cribriform proliferation which is not 
transluminal.60 
Criteria for diagnosis of prostatic adenocarcinoma64 
Major criteria 
• Architectural: infiltrative small glands or cribriform glands too large or 
irregular to represent HGPIN 
• Single cell layer (absence of basal cells) 
• Nuclear atypia: nuclear and nucleolar enlargement 
Minor criteria 
• Intraluminal wispy blue mucin (blue-tinged mucinous secretions) 
• Pink amorphous secretions 
• Mitotic figures 
• Intraluminal crystalloids 
• Adjacent high-grade PIN 
• Amphophilic cytoplasm 
• Nuclear hyperchromasia 
Collagenous micronodules and glomerulaions along with perineural invasion 
are features of prostate cancer, other than metastasis. 
Perineural invasion (PNI) 
Perineural invasion by malignant cells can be found in 11–37% of needle 
biopsy specimens with carcinoma, but with minimal or limited prostate cancer 
occurs only in 0–3% of tissue. In the absence of other features in support of 
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carcinoma, the glands in question should circumferentially (i.e. 100%) surround the 
nerve in order for perineural invasion to be diagnostic of adenocarcinoma. (Fig.26) 
In cases where there are other histological features supporting the diagnosis of 
prostate cancer, perineural invasion that is less than circumferential can help to form 
a diagnosis of malignancy. Benign glands abutting the prostatic peripheral nerve 
needs to be distinguished from true PNI which is representative of adenocarcinoma 
of the prostate.65, 66  
David Merrilees et al.,67 in his study on PNI in radical prostatectomy observed 
90% of cases with this feature. Diameter of nerves exhibiting perineural invasion 
ranged from 11 to 680 μm. Perineural invasion density ranged from 6 to 96%.  
Lymphovascular Invasion 
Lymphovascular invasion (LVI) indicates whether microscopic lymph-
vascular invasion is identified. LVI includes vascular invasion, lymphatic invasion, 
or lymphovascular invasion. (Fig.27) By AJCC convention, LVI does not affect the 
Tumor(T) category indicating local extent of tumor unless specifically included in 
the definition of a T category.15 
Extra prostatic Extension: 
Extra prostatic extension (EPE) is the presence of tumor beyond the confines 
of the prostate gland. Tumor involves the loose connective tissue beyond or in the 
plane of fat, even in the absence of direct contact between the tumor and the 
adipocytes, indicates EPE. When perineural spaces in the neurovascular bundles are 
involved by the tumor, even in the absence of periprostatic fat involvement may also 
be reported as EPE. EPE is determined when the tumor extends beyond the confines 
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of the normal glandular prostate, in anterior and apical prostate and bladder neck 
regions areas where there is paucity of fat. The specific location(s) and the number 
of sites (blocks) of EPE are useful to report. Labelled as focal and nonfocal EPE. 
Focal EPE is involvement of a few neoplastic glands, outside the prostate or a tumor 
involving less than one HPF in 1 or 2 sections and more extensive spread beyond the 
prostatic edge is nonfocal EPE.68 
Grading of Prostatic cancer: 
Of the many proposed systems, currently the most widely accepted and used 
is the Gleason system for the grading of prostate cancer. Most recently, the system 
has been endorsed by the World Health Organization. Gleason’s system is based 
entirely on the architectural pattern of the tumor, without taking cytologic features 
into account. It was (and remains) relatively unique among pathologic grading 
systems. 
In 1966, Donald F. Gleason, created the Gleason grading system based 
architectural features of prostate cancer on low-power examination. The initial 
description of this system was based on a study of 270 patients from the 
Minneapolis Veterans Administration Hospital (Minneapolis, Minnesota). Later the 
study was expanded to include 1032 men in 1974. With more and more experience, 
Gleason made further refinements to the system in 1974 and 1977.69,70 
Veteran’s Administration Cooperative Urological Research Group 
(VACURG) was established in the 1960s to study the treatment modalities and 
prognostic parameters in carcinoma prostate. All PCa’s were graded by Dr. Gleason 
as part of the study, which is still being used with modifications.71 
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Five grading categories, designated patterns, were defined as follows: 
Pattern 1:  Very well differentiated small and closely packed glands forming a 
circumscribed tumor mass. 
Pattern 2:  Similar to pattern 1 but with less well circumscribed glands showing 
greater variation in both size and shape. 
Pattern 3:  Well-formed discrete units of variable sized individual glands. (Fig.28) 
Pattern 4:  Closely packed, poorly formed/ fused (Fig.29) / glomeruloid / cribriform 
glands. (Fig.30) 
Pattern 5:  Lack of gland formation with sheets of tumor/ individual cells/ cords/ 
solid nests of cells and linear arrays. (Fig.31) 
In this architectural system, all tumors fall into a 5-grade system 
representing a continuum of progressively complex morphologies. More than one 
histological pattern was present in most cases and he designated the predominant 
pattern as the primary pattern, while the subordinate pattern was designated the 
secondary pattern.  
The Gleason score is obtained by adding primary and secondary patterns in a 
total out of ten. The pattern is considered as both the primary and secondary, if only 
one pattern is present then this. 
Grading system15, 57 
Current system differs from original and scores 2 to 5 are no longer assigned 
on biopsy. 
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Grade group 1  Gleason score 6 - Only individual discrete well-formed glands 
Grade group 2  Gleason score 3+4 = 7 - Predominantly well-formed glands with 
lesser component of poorly formed/fused/cribriform glands. 
Grade group 3  Gleason score 4+3 = 7 - Predominantly poorly formed/ fused/ 
cribriform glands with lesser component of well-formed 
glands. 
Grade group 4  Gleason score 4+4 = 8; 3+5 = 8; 5+3 = 8 - Only poorly 
formed/fused/cribriform glands (or) predominantly well-
formed glands and lesser component lacking glands (or) 
predominantly lacking glands and lesser component of well-
formed glands 
Grade group 5  Gleason scores 9-10 - Lack gland formation (or with necrosis) 
with or without poorly formed / fused / cribriform glands 
Description of the amount of pattern 4 in the setting of Gleason Score 7 (3+ 
4 versus 4+3) is prognostically important. Presence of any Gleason pattern 4 is 
typically considered clinically significant prostate cancer and is often important in 
the clinical decision-making process. In the most recent Partin tables for prognostic 
purposes, Gleason score 7 (3+4) and Gleason score 7 (4+3) are considered 
separately.72 
Lower-grade secondary patterns comprising <5% of the tumor area should be 
ignored in a high grade cancer. For example, a needle biopsy core that is 100% 
involved by cancer, with 98% Gleason pattern 4 and 2% Gleason pattern 3, would 
be diagnosed as Gleason score 4+4=8. While any proportion of higher secondary 
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pattern, even if <5% of tumor area, should contribute to the score. For example a 
needle biopsy that is entirely involved by cancer with 98% Gleason pattern 3 and 
2% Gleason pattern 4 would be diagnosed as Gleason score 3+4=7.  
If a tertiary pattern was present then the final score should be derived from 
the primary pattern, with the (higher) tertiary pattern being reassigned as the 
secondary pattern. Consequently, tumors with Gleason score 3+4 and a tertiary 
pattern 5 would be recorded as Gleason score 3+5=8. In cases where there are three 
patterns consisting of patterns 2, 3, and 4, one would ignore the pattern 2 and the 
biopsy would be called Gleason score 3+4=7 or Gleason score 4+3=7, depending on 
whether pattern 3 or pattern 4 was more prevalent. 
Needle biopsy with different cores showing different grades: To assign 
individual Gleason scores to separate cores as long as the cores were submitted in 
separate containers or the cores were in the same container yet specified by the 
urologist as to their location (ie, by different color inks). In addition to giving 
separate cores individual Gleason scores, one has the option to also give an overall 
score at the end of the case.15, 57 
Staging 
The 2010 revision of the American Joint Committee on Cancer⁄ Union 
International Centre on Cancer (AJCC⁄ UICC) tumor, node and metastasis (TNM) 
system is the most widely used staging system at this time. Pathologic staging is 
usually performed after surgical resection of the primary tumor.  
Pathologic staging depends on pathologic documentation of the anatomic 
extent of disease, whether or not the primary tumor has been completely removed. 
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pT entails a resection of the primary tumor or biopsy adequate to evaluate the 
highest pT category, pN entails removal of nodes adequate to validate lymph node 
metastasis, and pM implies microscopic examination of distant lesions. 15 
Intraprostatic adipose tissue does not exist, so identification of fat invasion in 
needle biopsies constitutes T3a cancer. Similarly, T3b cancer can be identified by 
needle biopsy of seminal vesicles. Because of the availability of various imaging 
tools for the detection histopathological assessment of bone biopsy is rarely needed 
for the diagnosis of bone metastasis.73 
Molecular genetics 
Great progress in understanding the molecular basis of PCa and the genomic 
alterations of the underlying the disease has occurred over the past decade. Next-
generation sequencing has allowed the classification of PCa at multiple strata of 
molecular information, incorporating data at genomic, proteomic, transcriptomic, 
and epigenetic levels. 
In early genomic and transcriptomic analyses, prostate tumors were able to 
be stratified based on patterns of somatic copy number alterations (SCNAs) and 
mRNA expression signatures. Considerable evidence exists that PCa is driven by 
cardinal genetic alterations that activate oncogenes and inactivate tumor suppressors, 
these result most commonly from structural genomic changes including deletions 
involving the NKX3.1 and phosphatase and tensin homologue tumor suppressor 
genes (PTEN), and amplifications of the androgen receptor (AR) and MYC genes. 
Recently published data from The Cancer Genome Atlas (TCGA) supports 
the major molecular subclasses of localized PCa can be divided into E26 
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transformation specific (ETS) - rearrangement PCa (PCa with rearrangements and 
overexpression of ERG, ETS Variant 1 (ETV1), ETV4, or other ETS family 
transcription factors), Speckle-type POZ protein (SPOP)/Chromodomain Helicase 
DNA Binding Protein 1(CHD1) altered cancers and several smaller categories.74  
ETS-rearranged tumors are generally enriched in genomic alterations in the 
Phosphatidyl Inositide 3-Kinase (PI3K) and p53 signaling pathways, whereas other 
specific SCNAs predominate in SPOP-mutant cancers. A subset of ETS-negative 
cancers (including SPOP mutant cancers) show overexpression of Kazal type 1 
(SPINK1), a secreted serine peptidase inhibitor, associated with poor prognostic 
features, is another marker commonly used for disease classification. Those 
overexpressing SPINK1, hold promise as treatment targets.75 In contrast to well 
defined genomic lesions, protein altering point mutations are uncommon in PCa, 
which makes it one of the cancers with lowest rate of such mutations.  
Studies have shown fusion of TMPRSS2 and ERG loci at the 
chromosomal level with subsequent overexpression of the TMPRSS2: ERG 
transcript and truncated ERG protein product is essentially 100% specific for the 
presence of PCa. 
  The ability of a solid tumor to grow without developing its own vascular 
network is limited by simple oxygen and or nutrient diffusion capacity. The 
development of a pro-angiogenic capability is necessary for continued growth of 
tumor. In many tumor types this occurs as an early-stage to mid-stage event in the 
carcinogenic process as a well-defined transition, termed the angiogenic switch. 
Vascular endothelial growth factor (VEGF), placental growth factor, angiopoietin 1, 
fibroblast growth factors, platelet-derived growth factor (PDGF) and epidermal 
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growth factor are various pro-angiogenic factors that have been shown to play roles 
in new blood vessel formation during tumor growth.76 
Although significant biological activity can usually be demonstrated in 
preclinical models, number of agents that interfere with VEGF ⁄ VEGFR signaling 
have been developed. A non-receptor tyrosine kinase, Src also mediates a diverse 
array of biological effects in different cell types. Bevacizumab is a humanized 
monoclonal antibody against VEGF that inhibits VEGFR signaling by binding to 
and neutralizing the ligand. Other newer therapeutic agents developed include 
Sunitinib, Aflibercept and Dasatinib.  
Isocitrate dehydrogenase-1 (IDH1) metabolic enzyme, is recurrently mutated 
in several human malignancies including acute myeloid leukemia and gliomas and 
result in a methylator phenotype. Increased production of the oncometabolite, 2-
hydroxyglutarate via neomorphic activity of IDH1 gained through characteristic 
mutations is thought to result in the inhibition of Tet Methylcytosine Dioxygenase 2, 
thereby resulting in hypermethylation across the genome.77 
The integration of multiple genomic platforms in primary PCa allowed for the 
identification of this rare, novel molecular subclass of PCa which is characterized by 
IDH1 mutations, most notably at residue R132. These cancers were found to be 
associated with early age of onset, few SCNAs, and similar to IDH1-mutant gliomas 
and acute myeloid leukemias, vast, genome-wide hypermethylation, although at 
disease-specific loci. Although this mutation is uncommon, this mutation may be 
clinically actionable, as clinical trials with IDH1 inhibitors specific to R132 IDH1- 
mutants are ongoing in acute myelogenous leukemia and other malignancies.78 
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IMMUNOHISTOCHEMISTRY 
Immunohistochemistry (IHC) is a method for locating specific antigens in 
tissues based on antigen antibody recognition. It exploits the specificity of the 
binding antibody with the antigen at a light microscopic level.79 
The enzymatic label (Horseradish peroxidase) developed by Avaremeas and 
by Nakane and colleagues, allowed visualization of the labelled antibody by light 
microscopy in the presence of a suitable colourogenic substrate system. 
Taylor in 1974 successfully demonstrated antigens in formalin fixed paraffin 
embedded (FFPE) tissues. Critical issue in the development of immunoperoxidase 
technique was related to the need to achieve greater sensitivity that would facilitate 
staining of FFPE tissues from a simple one step direct conjugate method to multiple 
step detection techniques such as peroxidase antiperoxidase (PAP), avidin-biotin 
conjugate (ABC), and biotin streptavidin (B-SA) methods and would eventually lead 
to amplification methods (such as tyramide) and highly sensitive polymer-based 
labelling system.80 
The use of IHC as an auxiliary in the diagnosis of adenocarcinoma is a 
common practice in Uropathology. Application of Immunohistochemistry in PCa 
includes confirmation or exclusion of prostate cancer, identification of atypical cells 
within benign prostatic appearences, identification of genotypic subtypes and finally 
prediction of behaviour of prostate cancer. It also helps to distinguish benign mimics 
from malignancy. Markers fall into second category are those employed as 
diagnostic adjuncts (CK34βE12) and those identify cellular phenotypic change. 
Markers used to identify prostatic origin of neoplasm are PSA and PSMA. To avoid 
rebiopsies and to enhance their diagnostic capabilities, Pathologists frequently use 
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immunohistochemistry. Still there are reports of false-positives and false-negatives 
for use of the combined CK34βE12 and p63 cocktail.  
Recognition of mimickers of adenocarcinoma by careful routine microscopy 
coupled with Immunhistochemistry will lead to a correct diagnosis. 
Immunohistochemical studies aimed at identifying prostatic basal cells (CK34βE12, 
CK5/6, p63), prostatic secretory cells (PSA, PAP, CD57), neuroendocrine cells 
(chromogranin, synaptophysin) and inflammatory cells (LCA, CD68) may be 
required to resolve this diagnostic dilemma. Another marker α-methylacyl-CoA 
racemase (P504S) appears to be of value in supporting a diagnosis of 
adenocarcinoma, especially when one is dealing with small foci.81 
PSA is a 33-kD serine protease that is used widely to confirm immuno 
histochemically the prostatic origin of metastatic carcinoma. It is not entirely 
prostate-specific, as PSA has also been detected in carcinomas of the ovary and the 
breast, including male breast cancer and other tissues. 
Prostate-specific membrane antigen (PSMA) is a transmembrane protein that 
is expressed strongly by most PCa and their metastases and has therefore been 
recommend as a diagnostic marker.82 PSA and PSMA are both targets of androgen 
signalling and is also regulated in prostate cancer. It is non-specific as it is expressed 
by other human tissues. 
Novel markers available are Prostein, coded by the gene SLC45a3, first 
identified as a prostate-specific transcript by Xu et al.83 in 2001 and ERG 
expression although not sensitive is highly specific for carcinoma prostate in a 
metastatic site.  
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p63: 
p63, a homologue is expressed in the basal cells of prostate, located in 3q27. 
This encodes six isoforms, distinction between these isoforms by mRNA expression 
is important when interpreting the biological phenotype of cells, that contain 
identified protein. Shift in balance between different isoforms inhibits or even 
promotes normal or malignant growth. This depends upon expression of other co- 
acting genes simultaneously. 84 
The use of antibodies against p63 and high molecular weight cytokeratin has 
been recommended as adjuncts in confirming PCa.   
High Molecular Weight Cytokeratin (HMWCK): 
Originally reported in 1983, monoclonal antibody clone 34βE12 (earlier 
known as CK 903, EAB 903, hP 34) to HMWCK’s. This immunostain is used to 
demonstrate basal cells which in turn discriminate between early prostatic 
malignancy and atypia from non-neoplastic mimickers of carcinoma. In a 
comparison study of basal cell detection, have found out that it should be employed 
only after use of microwave retrival protocol. HMWCK assists in differentiating 
basal call hyperplasia from carcinoma or high grade PIN.85 
Qualitative differences are identified between CK34βE12 and p63 in the 
staining pattern and have been found significant where p63 staining is offered in 
diagnostic utility than 34βE12. In such condition p63 appeared as strong but 
discontinuous in atypical glands and adjacent benign glands. But CK34βE12 failed 
to stain the above mentioned structures. This emphasises the necessity for use of 
defined protocol. To avoid such difficulties, various cocktails of antibodies are 
suggested (eg. AMCAR). 
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According to Epstein et al., basal cell cytokeratin is expressed in up to 0.3% 
of cases, the negativity of basal cell markers is complemented by a positive indicator 
of malignancy. Basal cells in the prostate can be labelled by a wide range of other 
markers that can be employed diagnostically. Among others, P-cadherin, D2-40, 
CD109 or BCL-2 has been suggested.  
Gown and Vogel86 in 1984, reported the use of a monoclonal antibody anti-
high molecular weight cytokeratin (CK34βE12) to mark basal cells of the prostate 
that was later demonstrated as a characteristic of benign glands that retain the basal 
cell layer.  
In another series, Wojno and Epstein87 used CK34βE12 to diagnose 
adenocarcinoma in suspicious glands identified in needle prostate biopsies. 
Shah et al.88 later proposed the combined use of p63, a homolog of the p53 
tumor suppressor protein, as an auxiliary marker for the determination of cancer 
since it is also a protein expressed selectively by the basal cells of epithelial organs, 
including the prostate gland.  
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Study Design: Cross sectional Study of retrospective data and present data. 
Retrospective data from January 2016 to December 2016 was used. 
Study Setting: Department of Pathology, Sree Mookambika Institute of Medical 
Sciences. 
Duration of study: Two years 
Number of groups to be studied: 1 
Detailed description of group: All prostatic specimens received in 
histopathological lab 
Sample size of each group: One group with 50 samples 
Total sample size of study: 50 
Scientific basis of sample size used in study: 
Sample size was calculated using the formula 
N = 4pq/d2 
P = Prevalence 
q = 100 – p 
d = Allowable error (5-20%p) 
Prevalence: 68%  
4 x 68 x 32= 8704 
20% of 68 = 13.6 
8704/ (13.6)2= 47 Samples 
Sampling technique: Convenient Sampling. 
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Inclusion criteria: 
 All prostatic biopsies (received from Department of Urology for 
histopathological examination). 
Exclusion criteria: 
 Those Cases where specimen sample seems inadequate for histopathological 
reporting.  
 Histopathologically proved metastatic carcinomas to prostate.  
 Men below 40 years of age. 
Procedure in detail: 
After getting approval from Institutional Human Ethical Committee (IHEC), 
clinical history and results of relevant investigations done were collected from the 
patient case files. Prostatic needle biopsies and Transurethral resection of prostate 
(TURP) specimens were the usual specimens received in the Pathology department 
in adequate 10% formalin. 
After a detailed specimen description, sampling was done. Entire tissue was 
processed in needle biopsies. In cases of TURP approximately 2 grams of tissue was 
processed for first 12 grams in 6 cassettes and then for every 5 grams of tissue bit 
one cassette of 2 grams is added and embedded. The tissue bits were processed 
manually and paraffin blocks were prepared. 
Tissue sections of 4- 6μm thickness were cut and stained by haematoxylin 
and eosin (H & E) for histopathological study. The sections were studied extensively 
and the results were noted in the proforma.  
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For retrospective cases, the histopathology reports, slides and paraffin blocks 
were retrieved from the archives from January 2016 to December 2016. Sections 
were cut from the paraffin blocks in a similar manner. 
Then 3-4 μm sections were cut from a paraffin block of premalignant & 
malignant tissues and taken on glass slide coated with adhesive (Poly- Lysine) for 
immunohistochemistry (IHC) to detect for High molecular weight Cytokeratin 
(Cytokeratin 34BetaE12 /keratin 903) and p63. Procedure in brief as follows,  
Air dry the slide for 2 hours at 58ºC. Deparaffinise, dehydrate and rehydrate 
tissues. Subject tissues to heat epitope retrieval using immune DNA retriever citrate. 
Wash IHC wash buffer. Place slide in polydetector peroxidase blocker for 5 minutes. 
Wash IHC wash buffer. Incubate sections with the primary antibody. Wash IHC 
wash buffer. Cover tissues with polydetector HRP label. Incubate for 45 minutes. 
Rinse with IHC wash buffer. Prepare DAB (deaminobenzidine) by adding one drop 
of polydetector DAB chromogen per ml of polydetector DAB buffer and mix. Cover 
tissue with prepared DAB substrate chromogen solution. Incubate for 5 minutes. 
Rinse with Deionised water. Counterstain with hematoxylin, then dehydrate, clear 
and mount the slide with DPX. Positive and negative controls will be run with each 
batch of slides. 
H &E stained slides were studied for the tumor histology - benign or 
premalignant or malignant, benign mimickers of malignancy, inflammation and 
Gleason scoring system in case of malignancies. The immunostained slides were 
examined for basal cell cytoplasmic staining of High molecular weight cytokeratin 
(CK 34BetaE12) and nuclear staining in P63. 
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Basal cell staining intensity was scored as follows: 1 (negative), 2 (weak), 3 
(moderate) or 4 (strong positive). Percentage basal cell staining was scored from 0-
100%. Basal cell staining was considered positive if the density was 2+ or more and 
>10% glands were stained and negative if the score was 1+ or less and ≤ 10% of the 
glands were stained. 
Statistical methods of analysis 
1)  Significance level decided before starting of study: 5% 
2)  Statistical test used in data analysis: Logistic Regression Analysis & Chi- 
Square test 
3)  Software used for statistical analysis: 
o Data was entered in Microsoft Excel 
o Analysis was by SPSS Software Trial Version 20.0. 
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The total number of prostatic biopsies studied during the period of two years 
was 50.  
AGE DISTRIBUTION: 
Table 1 : Age Distribution 
Age Range No. of patients Percentage % 
50-59 3 6 
60-69 22 44 
70-79 19 38 
80-89 5 10 
90 – 99 1 2 
Total 50 100 
 
 
Fig. 1: Age Distribution 
 
Most common age group sampled were between 60 to 69 years.  
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CLINICAL PRESENTATION 
Table 2 : Clinical Presentation 
 
 
Fig. 2: Clinical Presentation 
 
Majority of the patients presents with urinary symptoms like urgency, 
increased frequency and dribbling and hard prostate on digital rectal examination. 
Hard prostate alone was seen in 4% of the cases detected incidentally. 
 
Urinary symptoms
48%
Hard prostate on 
DRE
4%
Both
48%
CLINICAL PRESENTATION 
Urinary symptoms Hard prostate on DRE Both
Clinical Presentation Frequency Percentage % 
Urinary symptoms 24 48 
Hard prostate alone on DRE  2 4 
Both features 24 48 
Total 50 100 
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NATURE OF SPECIMEN 
Table 3: Nature of Specimen 
Nature of specimen Frequency Percentage % 
TURP 39 78 
Trucut biopsy 11 22 
Total 50 100 
 
 
Fig. 3: Nature of Specimen 
TURP specimens accounts for 78% during this study period. 
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H & E DIAGNOSIS 
Table 4: H & E Diagnosis 
 
DIAGNOSIS Frequency Percentage % 
Benign (hyperplasia) 32 64 
High grade PIN 1 2 
Carcinoma 17 34 
Total 50 100 
 
 
Fig. 4: H & E Diagnosis 
A histopathological diagnosis was made by H and E; most were benign, 
amounting to 64%. 34 % showed carcinoma and 2% was diagnosed as PIN. 
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INFLAMMATION AND INFARCTION 
Table 5: Inflammation and Infarction  
Inflammation Frequency Percentage % 
Prostatitis 14 28 
Granulomatous prostatitis 1 2 
Abscess 4 8 
Infarction 4 8 
Absent 27 54 
Total 50 100 
 
 
Fig. 5:  Inflammation and Infarction 
Prostatitis was seen in association with Nodular hyperplasia of prostate. 
Diagnosed only in the absence of malignancy, High grade PIN and atypical 
hyperplasia. Prostatitis being the most common type 38%. Granulomatous prostatitis 
was rare and accounts for 2%. Abscess was seen in 8% of the cases. 
28%
2%
8%
8%
54%
INFLAMMATION AND INFARCTION
Prostatitis Granulomatous Abscess Infarction None
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PSEUDO NEOPLASTIC LESIONS 
Table 6: Pseudo Neoplastic Lesions 
Pseudo Neoplastic Lesions Frequency Percentage % 
Basal cell hyperplasia 16 32 
Squamous metaplasia 3 6 
Atrophy 0 0 
Absent 31 62 
Total 50 100 
 
 
Fig. 6: Pseudo Neoplastic Lesions 
Among the various pseudo neoplastic lesions basal cell hyperplasia and 
squamous metaplasia were noted. Basal cell hyperplasia was seen in 32% cases and 
in association with benign prostatic hyperplasia. Squamous metaplasia notes in 6% 
of the cases. 
32%
6%
0%
62%
PSEUDONEOPLASTIC LESIONS
Basal cell hyperplasia Squamous metaplasia Atrophy Nil
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HISTOPATHOLOGICAL EXAMINATION: ARCHITECTURE 
The following architectural features were studied. More than one finding was 
allowed in the same biopsy. 
Table 7: Histopathological Examination: Architecture 
Architectural Feature Frequency Percentage 
Benign glands 32 64 
Small neoplastic glands 4 8 
Small and cribriform glands 10 20 
Cribriform and sheets 3 6 
Sheets 1 2 
Total 50 100 
 
 
Fig. 7: Histopathological Examination: Architecture 
Benign glands predominate and accounts for 64% followed by small and 
cribriform glands 20% with the least one being sheets 2% 
64%20%
8%
6% 2%
HISTOPATHOLOGICAL EXAMINATION: ARCHITECTURE
Benign glands Small neoplastic glands Small and cribriform glands
Cribriform and sheets Sheets
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HISTOPATHOLOGY: CYTOLOGICAL FEATURE 
Table 8: Histopathology: Cytological Feature 
Cytological Feature Frequency Percentage % 
Nucleomegaly only 5 10 
Nuclear Pleomorphism and nucleoli 12 24 
Signet ring cell 1 2 
None 32 64 
Total 50 100 
 
 
Fig. 8: Histopathology: Cytological Feature 
Cytological features suggest presence of malignant glands – nuclear 
pleomorphism and nucleoli being the most common finding seen in carcinoma, 
followed by nucleomegaly in High Grade PIN and in atypical hyperplasia. 
10 %
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HISTOPATHOLOGY: CYTOLOGICAL FEATURE
Nucleomegaly only Nuclear pleomorphism and nucleoli Signet ring cell None
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EVALUATION OF GLEASON SCORE: 
Table 9: Evaluation of Gleason Score 
Gleason Score Number of cases Percentage % 
3 + 3 3 17.5 
3 + 4 7 41 
4 + 3 3 17.5 
4 + 4,3+5,5+3 0 0 
4 + 5 1 6 
5 + 4 2 12 
5 + 5 1 6 
Total 17 100 
   
 
Fig. 9: Evaluation of Gleason Score  
The predominant pattern was 3, 4 amounting to 41% and followed by 3,3 
and 4,3  each of which showed 17.5%. None of the cases shows tertiary component.  
17.5%
41%
17.5%
0%
6%
12%
6%
GLEASONS SCORE
3+3 3+4 4+3 4+4,5+3, 3+5 4+5 5+4 5+5
Results 
 Page 55 
 
DIAGNOSIS OF CARCINOMA: GLEASON SCORE 
Table 10: Diagnosis of Carcinoma: Gleason Grade Group 
Gleason Group Number of cases Percentage % 
Group 1 3 18 
Group 2 7 41 
Group 3 3 18 
Group 4 0 0 
Group 5 4 23 
Total 17 100 
 
 
Fig. 10: Gleason grade 
The most common Gleason score encountered were grade 2(41%) followed 
by Score 1 and 3(18%) 
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OTHER SPECIFIC FEATURES OF MALIGNANCY 
Table 11: Other Specific features of malignancy 
Feature Frequency Percentage % 
Perineural invasion 8 46 
Lymphovascular invasion 2 12 
Glomerulations 2 12 
Extraprostatic extension 0 0 
Both perineural invasion and LV emboli 4 24 
Absent 1 6 
Total 17 100 
 
 
Fig. 11: Other specific features of malignancy 
Of the absolute features of malignancy studied, PNI was most common, seen 
in 46% of all carcinoma followed by lymphovascular emboli 12%. Both are seen in 
24% of cases. 
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SPECIFIC FEATURES OF MALIGNANCY
Perineural invasion Lymphovascular invasion Glomerulation
Extraprostatic extension Both perineural and LV invasion None
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PERINEURAL INVASION 
Table 12: Perineural invasion and relation with Gleason score 
Gleason score Frequency Percentage % 
Score 6 1 8 
Score 7 7 58 
Score 8 0 0 
Score 9 3 26 
Score 10 1 8 
Total 12 100 
 
 
Fig. 12: Perineural Invasion 
Perineural invasion is associated with Gleason score 7 is 58% and score 9 is 
26%. 
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HISTOPATHOLOGY: INTRAGLANDULAR CONTENTS 
Table 13: Histopathology: Intraglandular Contents 
Intraglandular Contents Frequency Percentage % 
Corpora amylacea 27 54 
Crystalloids 2 4 
Calcification 3 6 
Wispy blue mucin 0 0 
Crystalloid and eosinophilic debri 1 2 
None 17 34 
Total 50 100 
 
 
Fig. 13: Histopathology: Intraglandular Contents 
The most common intraglandular finding was corpora amylacea, seen only in 
benign glands. Crystalloids and eosinophilic material, that suggest malignancy was 
seen in 4 and 1 % of cases respectively. 
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HISTOPATHOLOGY: INTRAGLANDULAR CONTENTS
Corpora Amylacea Crystalloids Calcification
Wispy blue mucin Crytallois and eosinophilc debri None
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IMMUNOHISTOLOGICAL EVALUATION OF PREMALIGNANT AND 
MALIGNANT LESIONS 
A total of 18 cases were diagnosed as premalignant and malignant. Presence 
or absence of basal cells are important in differentiating malignant cases from 
benign and pseudo neoplastic lesions. These basal cells are present in benign glands 
but are completely absent in malignant glands. To identify the basal cells, basal cell 
markers like p63 and CK 34BetaE12 are useful. P63 stains nuclear positivity while 
CK 34BetaE12 is cytoplasmic.  
Basal cell staining density was scored as  
3+ -  strong  
2+ -  moderate 
1+ -  weak  
0   -  negative  
Percentage of basal cell staining was scored from 0% to 100%.  
Basal cell staining was considered positive only if the staining density was 2+ or 
more and >10% of the glands were stained 
Basal cell staining was considered negative if the score was 1+ or less and ≤10% of 
the glands were stained. 
For both stains when staining is positive it is considered benign, (Fig.32, 34) and is 
considered malignant if basal staining is negative. (Fig.33, 35). Intermediate between 
these is the PIN which shows intermittent or patchy staining. 
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Table 14: IHC Evaluation 
Sl. No HP. NO 
p63 CK 34BetaE12 
IHC 
Diagnosis 
Staining 
Other 
findings 
Staining 
Other 
findings 
1 713/16 0 - 0 - Malignant 
2 839/16 
3+ 
(intermittent) 
- 
2+ 
(intermittent) 
- PIN 
3 2308/16 0 
Entrapped 
benign glands 
0 
Entrapped 
benign glands 
Malignant 
4 551/16 0  0  Malignant 
5 906/16 0  1+(<10%)  Malignant 
6 1061/17 0  0  Malignant 
7 864/17 1+  1+(<10%)  Malignant 
8 1263/17 0  0  Malignant 
9 1555/17 0  0  Malignant 
10 1178/17 0  1+(<10%)  Malignant 
11 798/17 0 
Entrapped 
benign glands 
0 
Entrapped 
benign glands 
Malignant 
12 1558/17 0  0  Malignant 
13 347/17 0  0  Malignant 
14 3631/17 0 
Entrapped 
benign glands 
0 
Entrapped 
benign glands 
Malignant 
15 13/17 0  0  Malignant 
16 2299/17 0  1+ (<10%)  Malignant 
17 6678/17 0 
Entrapped 
benign glands 
0 
Entrapped 
benign glands 
Malignant 
18 2302/17 0  0  Malignant 
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Out of the 18 cases, 17 cases were diagnosed as malignancy. Among the 
malignancies one case stained with p63 showed staining (1+) but it was involving 
<10% of atypical glands. So this was considered malignant. 
Four cases stained with CK 34BetaE12 showed staining (1+) (Fig.36) and 
was involving <10% of glands and hence considered as malignant.  
Four of the cases showed few glands with continuous basal cell staining 
pattern. These are considered as entrapped benign glands (Fig.37) and correlated 
with H and E stained sections. This finding was noted only in TURP specimens. 
Remaining one case shows intermittent staining pattern, which was 
diagnosed as PIN. 
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Fig. 14:  Anatomy of Prostate 
 
 
 
Fig. 15:   Corpora Amylacea (10x) 
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Fig. 16:  TURP – Gross  
 
 
 
Fig. 17: Prostatic Abscess (4x) 
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Fig.18: Granulomatous Prostatitis (4x) 
 
 
 
 
Fig.19:  Benign Nodular Adenomyomatous Hyperplasia (4x) 
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Fig. 20: Squamous Metaplasia (10x) 
 
 
 
 
Fig. 21: Basal cell Hyperplasia (10x) 
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Fig. 22: High Grade PIN (4x) 
 
 
 
 
Fig. 23: Signet ring cells (40x) 
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Fig. 24: Atypical cells having eosinophilic cytoplasm vesicular nucleus, 
prominent nucleoli (40x) 
 
 
 
Fig. 25: Intraluminal Crystalloids (10x) 
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Fig. 26:  Perineural invasion (10x) 
 
 
 
 
Fig. 27:  Lymphovascular emboli (10x) 
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Fig. 28: Small well-formed glands – Gleason score 3 (4x) 
 
 
 
Fig.29: Fused glands – Gleason score 4 (4x) 
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Fig. 30: Cribriform pattern – Gleason score 4 (4x) 
 
 
 
Fig. 31: Sheets of tumor cells - Gleason score 5 (4x) 
 
 
Results 
 Page 71 
 
 
 
 
Fig. 32: Benign glands - p63 Nuclear positivity for basal cells (10x) 
 
 
 
Fig. 33: Malignant glands - p63 Absence of basal cells (10x) 
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Fig. 34: Benign glands – CK34betaE12 Cytoplasmic positivity for basal cells 
(10x) 
 
 
 
Fig. 35: Malignant glands – CK34BetaE12 Absence of basal cells (10x) 
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Fig. 36: CK34BetaE12 – 1+ staining pattern (10x) 
 
 
 
Fig. 37: CK34BetaE12 - Entrapped benign glands with presence of basal cells 
(10x) 
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Prostatic specimens constitute a good percentage of the surgical pathology 
workload. This study was undertaken to evaluate the various histological lesions in 
prostatic specimens.  
CLINICAL FEATURES: 
The age of the patients in our study ranged from 50 years to 93 years; 
however, the predominant population was in the 6th to 7 th decade with a mean age 
of 69 years. Mean age for non neoplastic and neoplastic cases was 71 and 76 
respectively. No significant difference was noted in the mean age of the both 
groups.  
The results of the present study agree with the studies by George and 
Thomas,89 in which the mean age was 66.81 years, and by Barakzai et al.,90 in which 
the mean age was 66.9 years. This is also similar to the screening procedures in the 
studies by Physicians Health Study (PHS) and the Health Professionals Follow-Up 
Study (HPFS).91. The decline in the number of cases beyond the age of 80 years 
reflects the average life span of people in our country.  
Most of the patients had nonspecific symptoms related to urinary tract; like 
urinary hesitancy, or repeated urinary tract infections along with hard prostate on 
digital rectal examination. 
SPECIMEN: 
Transurethral resection of prostate specimens were more compared to core 
needle biopsies accounting for 78% and 32% respectively. Most of the core biopsies 
are done for suspected malignancies and these were done from hard nodules under 
digital guidance.  
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PROSTATITIS: 
Prostatitis accounts for 42% of which chronic prostatitis is noted in 38% and 
abscess in 8% of the cases studied. Mittal et al.92 in a study of 185 prostatic 
specimens reported that prostatitis constituted 38.4% of the cases, of which 26.3% 
of cases were chronic prostatitis, and acute prostatitis with or without abscess 
formation was noted in 12.1% of cases.  
Granulomatous prostatitis was seen in 1 out of 50 cases (2%) similar to 
studies done by Anjorin et al.93 
Nickel et al., in their review, quotes the REDUCE94 (REduction by 
DUtasteride of prostate Cancer Events) trial, where 80% of patient biopsies were 
found to have some degree of inflammation. 
PSEUDONEOPLASTIC LESIONS:  
Pseudoneoplastic lesions includes basal cell hyperplasia, seminal vesicle, 
cowper’s gland, atrophy, cribriform hyperplasia, nephrogenic metaplasia and 
squamous metaplasia.  These lesions can cause confusion with malignancy. In our 
study BCH was the common entity in the pseudoneoplastic group and accounted for 
28% (14 cases) of the total cases. All cases had associated nodular hyperplasia of 
prostate. Thorson et al.95 studied 500 needle core biopsy samples and found the 
incidence of BCH in the setting of usual nodular hyperplasia to be in the range of 
3.1% to 8.9%. 
The present study also showed squamous metaplasia in 3 cases, accounting 
for 6% of the cases. Study done by Abdollahi et al., who found squamous cell 
metaplasia in 4 cases (0.3%) in their study.96 
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INTRALUMINAL CONTENTS: 
Intraluminal contents studied were corpora amylacea, eosinophilic dense 
material, crystalloids and wispy blue mucin. The most common finding was corpora 
amylacea, seen in 54% of the total biopsies received, but few of these were seen in 
cases with malignant diagnosis which are associated with Nodular hyperplasia of 
adjacent glands in TURP specimens. James D Christian et al97 observed that corpora 
amylacea were located in malignant acini in 0.4 % of needle biopsies. 
Of the other three intraglandular materials seen in malignancy, crystalloid 
was the most common accounting to 4 % of all biopsies. This is far less than that 
described by Del Rosario AD et al., 98 who observed such crystals in 14 to 36% of 
cancers. 
Varma et al., 99 has described presence of faintly basophilic intraluminal 
mucin in up to 52% of cases, but no such material was demonstrated in the present 
study probably because of different staining characteristics.  
HISTOPATHOLOGY 
The architectural features studied included normal prostatic glands, 
neoplastic small glands separated by stroma, fused glands and neoplastic cells 
forming sheets. Benign glands show double lining epithelium. Malignant glands 
show absence of basal layer along with cellular atypia. 
Benign prostatic glands were seen in 62% of cases and was the most 
common finding observed; but it is not exclusively seen in benign conditions. Sarah 
Karre et al100 observed that the intervening benign glands diagnosed as malignant 
should be included in assessing the tumor mass. 
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Small infiltrating glands, back to back arrangement of these glands and 
sheets of neoplastic cells, which are signs of malignancy, were seen in 38 % of cases. 
CELLULAR FEATURES 
The cellular feature studied included cytoplasmic amphophilia, nuclear 
pleomorphism, nucleomegaly and nucleoli. Nuclear pleomorphism was the most 
common finding, observed in upto 26% of cases which are malignant lesions. 
Nucleolar enlargement alone was seen in 10% of total cases. Nucleolar enlargement, 
as reviewed by Epstein constitutes one of the most important diagnostic features, but 
may be seen in benign mimickers as well. 
HIGH GRADE PIN: 
The presence of an isolated PIN (PIN in the absence of carcinoma) should be 
reported in biopsy specimens, especially if more than 1 site is involved. High-grade 
PIN in a biopsy without evidence of carcinoma has in the past been a risk factor for 
the presence of carcinoma on subsequent biopsies. But reporting of PIN in biopsies 
with carcinoma is considered optional.   
In our study High grade PIN accounts for 2% of the cases studies which is 
similar to studies done by Oliai et al,101 mean number of HGPIN glands was 1.36%.  
H & E DIAGNOSIS: 
In our study, of 50 cases, 32 (64%) were nonneoplastic lesions, premalignant 
lesions 1 (2%) whereas neoplastic lesions constituted 17 of the total cases (34 %). 
This agrees with the studies conducted by Mittal et al,93 Anjorin et al,94 and George 
et al,89 in which nonneoplastic lesions formed the bulk of the cases. 
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The prevalence of PCa in the present study was 34%, i.e., 17 of 50 cases. 
Similar results were obtained by Anjorin et al.94 and Rekhi et al102. Most cases of 
prostate cancer are diagnosed after 50 years of age, but prostate cancer can be seen 
in younger adults. The frequency increases with age. Majority of cases were seen in 
the age group of 71 to 80 years, closely followed by the age group of 61 to 70 years. 
The time trends in detection of carcinoma at an early age have been greatly affected 
because more and more latent cases are diagnosed with the increasing use of PSA.  
VOLUME OF TISSUE INVOLVES IN MALIGNANT CASES 
The designation of the percentage of cancer tissue in transurethral samples is 
important. When prostate cancer is discovered incidentally (i.e., discovered in 
specimens submitted for clinically benign disease, usually Nodular hyperplasia of 
prostate), the percentage involvement is used to determine the clinical T1 substage, 
with ≤5% involvement being T1a and >5% being T1b.  
For needle core biopsy specimens, the number of positive cores out of the total 
number of cores should always be reported, except in situations where fragmentation 
precludes accurate counting. The estimated percentage of prostatic tissue involved by 
tumor and/or the linear millimeters of the tumor should also be reported. 
In our study malignant cases was seen in 6 of the TURP specimens and 11 of 
the needle biopsy cases. All the specimens showed tumor volume more than 5% 
with a mean value of 66%. 
GLEASON’S SCORE (SUM): 
Gleason grading system is recommended for use in all prostatic specimens 
containing adenocarcinoma, with the exception of those showing treatment effects. 
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Gleason score is the sum of the primary (most predominant in terms of surface area 
of involvement) Gleason grade and the secondary (second most predominant) 
Gleason grade. In needle biopsy specimens, Gleason score is the sum of the primary 
(most predominant) Gleason grade and highest Gleason grade and is recommended 
that Gleason scores be assigned for each separately identified core. However, some 
pathologists may choose to report an overall Gleason score for that specimen. The 
highest Gleason score should be provided in the summary. 
In needle biopsy specimens where there is a minor secondary component 
(<5% of tumor) and where the secondary component is of higher grade, the latter 
was reported. Conversely, if a minor secondary pattern is of lower grade, it was not 
be reported. When more than 2 patterns are present, and the worst grade is neither 
the predominant nor the secondary grade, the predominant and highest grade was 
chosen to arrive at a score. For transurethral resection specimens, the above grading 
principles also apply. 
A score of 7(3+4 and 4+3) was seen predominantly, constituting 41% and 
17.5% respectively, a score of 6 and 9 showed equal proportion given in 17.5% and 
score of 10 is seen in 6% of the cases. Various other studies including ours highlight 
a score of 7 as a predominant score.103 
Based on the grade grouping endorsed by ISUP, our study showed group 
grade 2 as the predominant group amounting for 41% followed by group grade 1 and 
3 both of which showed 18%. 
Gleason score ≤6 were reported to have negligible risk of prostate cancer-
specific mortality at 15 to 20 years; hence the importance for scoring 7 and 
above.  
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Kiril et al104 states that grade 5 is a rare diagnosis seen in 4.1 % of cancer 
biopsies, he reviews ISUP guidelines which recommends even tertiary grade 5 be 
reported as secondary.  
OTHER FEATURES SPECIFIC FOR CARCINOMA: 
Three histopathological features diagnostic of carcinoma are glomerulations, 
lymphovascular invasion and perineural invasion (PNI). Perineural invasion is 
regarded as pathognomonic of prostate cancer if there is circumferential or 
intraneural invasion by the tumor cells.  
A study conducted on 302 needle biopsies by Bastacky et al.105 showed 
perineural invasion in 20% of biopsies with cancer which was less compared to our 
present study in which perineural invasion alone was found in 8 of the malignant 
cases (46%) and was not observed in any of the benign cases studied. 
Lymphovascular invasion alone was noted in 12% cases and both perineural 
and lymphovascular invasion noted in 24% in our present study. 
Glomerulation, which are cribriform proliferation that are not transluminal 
were considered as grade 4 and was noted in 12 % of cancer diagnosis. 
Extraprostatic extension is tumor involving loose connective tissue, even 
in the absence of direct contact between the tumor and the adipocytes and also 
when the tumor involves perineural spaces, even in the absence of periprostatic 
fat involvement. None of the cases in our study showed extra prostatic extension.  
IMMUNOHISTOCHEMISTRY: 
The IHC panel for PCa usually includes basal cell–specific marker p63 and 
CK34βE12. p63 is expressed in the nuclei of basal cells, whereas CK34βE12 stains 
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their cytoplasm. Negative staining must be interpreted with caution because 
cytokeratin is formalin sensitive and a progressive loss of immunoreactivity can be 
seen in prolonged formalin fixation.  
IHC was done 18 cases that showed atypical glands. The usefulness of 
CK34βE12 and p63 relies on the fact that PCa lacks basal cells; therefore, lack of 
basal cell staining in an atypical lesion lends support to the diagnosis of PCa, 
whereas the presence of basal cell staining in general rules out cancer, with the 
exception of rare cases of basal cell staining in typical PCa by reactivity to 
CK34βE12. Few benign glands showed lack of basal staining and some entrapped 
benign glands were noted in TURP specimens. 
Basal cell immunohistochemical analysis, however, has some limitations. A 
patchy staining pattern seen in certain atypical lesions might create diagnostic 
confusion. Oliai et all in their study have shown that rare lesions with the 
appearance of PCa show CK34βE12 staining in a basal cell distribution either from 
retention of basal cells by early invasive cancer or from HGPIN outpouching101 
p63 is slightly more sensitive in identifying basal cells than CK34βE12 
according to our study. Because compared to p63 four cases stained by the latter 
showed 1+ staining intensity. Shah et al88 similarly found that p63 is more sensitive 
than CK34βE12 in identifying the basal cells, particularly in TURP specimens, 
offering slight advantage over CK34βE12 in diagnostically challenging cases and thus 
p63 may be used as an alternative to CK34βE12 stain for difficult prostatic lesion. 
  Varma et al99 studied the deleterious effects of prolonged formalin fixation 
on the CK34βE12 staining pattern of benign prostate glands and its effects on 
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different antigen pretreatments. They concluded that CK34βE12 immunoreactivity 
is dependent on optimal fixation and the immunohistochemical protocol.  
Multhaupt et al106 found the critical role of antigen retrieval in CK34βE12 
immunoreactivity. 88% of benign glands in the transition zone obtained by TURP 
lost their antigenicity if antigen retrieval was not used. 
Parson et al107 did report a small percentage of PCa cases staining positive 
for both p63 and 34βE12. Similar positivity was observed by Varma et al.99 The 
staining intensity was very weak, occurred in <1% of cells, that was not significant 
to create any problem in interpretation. Possible explanations are false positive 
reactions because of formalin fixation, entrapped benign glands, PIN glands 
entrapped within malignant glands or heterogeneity within tumor. 
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Prostatic disease is responsible for significant mortality and morbidity in 
elderly men throughout the world. It is uncommon to under diagnose small focus of 
prostatic adenocarcinoma or over diagnose benign lesions mimicking cancer.  
Our study focused on all prostatic lesions – benign, premalignant and 
malignant. Most of the patients presented with urinary symptoms along with hard 
prostate on digital rectal examination. Nodular prostatic hyperplasia forms the major 
part of the study (64%). 36% cases showed histological diagnosis of cancer and 
atypical / suspicious glands. Though the diagnosis of prostatic carcinoma can be 
made on morphological features and graded according to Gleason’s grading, 
sometimes it can be challenging when pathologists are faced with certain problems 
like crushing artifact, limited tissue sample and benign mimickers. In such case, 
Immunohistochemistry using basal cell markers like p63, CK34βE12 can be useful. 
For both types of stains positive staining was taken as an evidence of 
benignity whereas negative staining was taken as malignancy and discontinuous or 
intermittent staining was taken as premalignant.  
Immunostains were done in 18 cases having suspicious and atypical glands. 
Out of these 18 cases 17(34%) were diagnosed as malignancy and one (2%) was 
diagnosed as PIN. It was found that immunohistochemical p63 staining is 
diagnostically reliable in identifying basal cells and compares favorably with 
CK34βE12 staining. In addition, p63 staining which shows a nuclear reaction is easy 
to interpret than CK34βE12 which shows cytoplasmic reaction. 
Absence of basal staining may be attributed to the true absence of basal cells 
or diminished or absent gene expression of basal cell markers. 1+ staining pattern 
with CK34βE12 was noted in 3 cases with atypical glands but this was less than 
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10%, hence diagnosed as malignancy. Technical variabilities including surgical 
procedures, formalin fixation and antigen retrieval methods could be another cause 
of negative basal cell reaction.  
This study has demonstrated that p63 has the same specificity and almost the 
same sensitivity as CK34BetaE12, and may also be utilized in distinguishing PCa 
from benign prostatic lesions and pseudo neoplastic lesions of prostate.  Ultimately, 
understanding the potential pitfalls of IHC stains and paying careful attention to 
morphologic details are crucial to prevent the false-positive and false-negative 
diagnosis. 
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 During the study period, 50 cases of prostatic biopsies were obtained and 
histomorphology studied.  
 Age distribution was between 50 – 93 years, with 44% falling between 6th – 7th 
decades. 
 Common manifestations were urinary symptoms like reduced flow, urinary 
incontinence and hard prostate on digital rectal examination.  
 Out of 50 cases 78% of the cases are Transurethral resection specimens.  
 64% cases were diagnosed as Nodular hyperplasia, 2% as PIN and the remaining 
34% was diagnosed as malignancy. 
 Prostatitis is more commonly noted along with nodular prostatic hyperplasia 
28%. Granulomatous was seen in 2% of the cases. 
 Pseudo neoplastic lesions like basal cell hyperplasia and squamous metaplasia 
were noted accounts for 32% and 6% respectively. 
 62% of the patients showed benign glands rest being atypical or suspicious 
glands. Atypical glands showed predominance of small glands and cribriform 
pattern (24%), cribriform and sheets in 6% and sheets of tumor cells alone was 
noted in 2% cases.  
 Corpora amylacea (54%) is the most common intraluminal contents and that is 
noted in benign glands. Luminal crystalloids seen in 4% of the cases and all 
were seen association with malignancy. 
 Adenocarcinoma diagnosed were graded according to Modified Gleason 
grading, IUSP 2015 guidelines. Gleason grade 2 was seen in 41% cases with 
score 3+4 = 7. 
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 One case with signet ring component noted, no other variants were detected. 
 Associated factors in malignancy like perineural invasion 46% lympho vascular 
emboli 12% were noted. Both findings were seen in 24% of the cases studied. 
Extra prostatic extension not detected.  
 Immunohistochemistry (p63 and CK34βE12) was done in 18 cases of 
malignancy and suspicious of malignancy. One case was diagnosed as High 
Grade PIN and remaining cases were confirmed as malignancy. 
 p63 is expressed in the nuclei of basal cells, whereas 34βE12 stains their 
cytoplasm. 4 cases showed entrapped benign glands. p63 is slightly more 
sensitive in identifying basal cells than CK34βE12 according to our study. 
Because compared to p63, four cases stained by CK34βE12 showed 1+ staining 
intensity. This false positive reaction may be because of formalin fixation and 
antigen retrieval.  
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Appendices 
 
APPENDIX - 1 
 
 
APPENDIX - 2 
 
 
APPENDIX - 3 
 
H & E STAINING: 
 Sections - 3-4 micron thickness  
 Deparaffinize in xylene – 2 changes 5 minutes each. 
 Rehydrate in absolute alcohol and 50% alcohol 1 min each. 
 Wash in running tap water for 5 minutes. 
 Stain with Harris hematoxylin for 10 minutes. 
 Running tap water wash for 5 minutes. 
 Differentiation with Acid alcohol 1 dip. 
 Running tap water wash for 5 minutes. 
 Stain with eosin for 30 seconds  
 75%, 80% and 95% alcohol 1 minute each 
 Absolute alcohol 1 minutes 
 Clear in xylene – 3 changes 1 minute each. 
 Mount with DPX. 
 
 
 
 
 
 
APPENDIX - 4 
 
IMMUNOHISTOCHEMICAL STAINING  
Thinner sections (3 microns) of formalin fixed paraffin embedded tissue 
blocks are taken on Poly L lysine coated slides, and processed through following 
steps: 
 Xylene I  5 min 
 Xylene II  5 min 
 Alcohol (100%) 1 min 
 Alcohol (50%) 5 min 
 Tap water  3 min 
 Buffer wash (Citrate buffer at pH 6.2) 
 Antigen retrieval by pressure cooker method 
 Wash in running tap water 5 minutes 
 Rinse in distilled water  
 Buffer wash (tris buffer) 2 x 5 minutes 
 Peroxidase block 5 minutes 
 Buffer wash 2 x 5 minutes 
 Power(protein) block 5 minutes 
 Incubate in Primary Antibody 30 minutes 
 Buffer wash 2 x 5 minutes 
 Super enhancer (incubation with Post primary) 30min 
 Buffer wash 2 x 5 minutes 
 Incubate with Polymer HPR 30 minutes 
 Buffer wash 2 x 5 minutes with gentle rocking 
 DAB (Freshly prepared) for 5 minutes 
 Running tap water 5 minutes 
 Hematoxylin counterstain for 15 seconds 
 Rinse in running tap water for 5 minutes 
 Dehydrate 
 Clearing 
 Mount in DPX 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
APPENDIX - 5 
 
GLEASON GRADE GROUPS: 
Grade 
Group 
  
 
Gleason 
Score 
Definition 
1 ≤6 Only individual discrete well-formed glands  
2 3+4=7 
Predominantly well-formed glands with lesser 
component of poorly formed/fused/cribriform glands  
3 4+3=7 
Predominantly poorly formed/fused/cribriform glands 
with lesser component of well-formed glands  
4 
4+4=8 Only poorly formed/fused/cribriform glands  
3+5=8 
Predominantly well-formed glands and lesser 
component  lacking glands (or with necrosis)  
5+3=8 
Predominantly lacking glands (or with necrosis) and 
lesser component of well-formed glands  
5 9-10 
Lack gland formation (or with necrosis) with or without 
poorly formed/fused/cribriform glands  
 
 
 
 
 
 
 
Illustration of various grades by Gleason. ISUP 2015 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX - 6 
 
 
CASE PROFORMA 
 
 
Identity Number        :                                 Date           : 
AGE/SEX                      :                                 Phone No  : 
ADDRESS                     : 
PRESENTING COMPLAINTS                : 
(Dysuria, Hesitancy, Frequency, 
Dribbling, Retention, Urgency, 
Hematuria, Fever) 
INVESTIGATIONS                                 : 
MACROSCOPY: 
 Type of specimen            : 
 Gross weight & measurement : 
 Added description                      : 
FINDING BY MICROSCOPY: 
Features Finding 
1.Number of fragments in needle biopsies 
   Number of fragments involved by tumor/ 
lesion 
 
2. Volume of tissue involved by tumor/ lesion  
3.  Appearance of glands 
· Nodular adenomatous hyperplasia 
· stromal hyperplasia  
· mixed epi and stromal hyperplasia  
· small glands 
· cribriform / fused glands 
. Sheets  
. Squamous Metaplasia 
. Basal cell hyperplasia 
4. Appearance of stroma 
· Fibrous hyperplasia 
· Stromal oedema 
  
5. Cell morphology 
. Nuclear pleomorphism 
. Nucleoli 
. Mitosis 
  
6. Inflammation and infarction 
. Prostatitis 
. Granulomatous inflammation 
. Abscess  
. Infarction 
. None 
  
7. Luminal contents 
· Corpora amylacea 
· Crystalloids 
· Mucinous secretion 
             . Eosinophilic debri 
             . Calcification  
  
8. PIN   
9. Malignancy +/- 
    If yes, volume of infiltrate 
  
10. Gleason scoring (malignancy) Gleaon’s grade: 
 Grade 1 
 Grade 2 
 Grade 3 
 Grade 4 
 Grade 5 
 3+3 
 3+4 
 4+3 
 4+4 
 5+3 
 3+5 
 5+5 
11. Associate prognostic factors: 
 Perineural invasion 
 LV emboli 
 Whispy mucinous material  
 
12. H & E Diagnosis 
 Benign  
 PIN 
 Carcinoma 
 
13. Immunostaining 
 Indication - atypical/suspicious glands 
 cytokeratin 34βE12 
 p63 
Positive % Negative % Others 
   
   
  
INFERENCE: 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX - 7 
 
 
ABBREVIATIONS 
AAH  -  Atypical Adenomatous Hyperplasia 
ABC  -  Avidin-Biotin Conjugate 
AJCC  -  American Joint Committee on Cancer 
ASAP  -  Atypical Small Acinar Proliferation 
CAP    -  College of American Pathologist 
DRE    -  Digital Rectal Examination 
ELISA  -  Enzyme Linked Immuno Sorbant Assay 
EPE    -  Extra Prostatic Extension 
FFPE  -  Formalin Fixed Paraffin Embedded 
H&E  -  Hematoxylin and Eosin 
IDH 1  -  Isocitrate Dehydrogenase 1 
ISUP  -  International Society of Urologic Pathology 
KLK3 -  Kallikrein-3 
LOH  -  Loss of Heterozygosity 
LVI  -  Lympho Vascular Invasion 
NIH  -  National Institute of Health 
PAP  -  Peroxidase Anti Peroxidase 
PCa -  Prostatic Carcinoma 
PIA -  Proliferating Inflammatory Atrophy 
PIN  -  Prostatic Intraepithelial Neoplasia 
PNI  -  Perineural Invasion 
PSA  -  Prostate Specific Antigen 
TURP -  Trans Urethral Resection of Prostate 
UICC  -  Union International Centre on Cancer 
VACURG  -  Veteran’s Administration Cooperative Urological Research Group 
WHO  -  World Health Organization 
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1 1358/16 71 1 1 0 1 1 3 2 1 0 0 0 0 1 2 4 2 4 0 
2 2031/16 64 1 1 0 1 3 1 0 1 0 0 0 0 1 2 4 2 4 0 
3 1984/16 65 1 1 0 1 1 2 0 1 0 0 0 0 1 2 4 2 4 0 
4 713/16 77 2 3 60 3 0 0 0 2 1 2 2 3 3 0 0 0 0 0 
5 2097/16 65 1 3 0 1 3 1 1 0 0 0 0 0 1 2 4 2 4 0 
6 2742/16 62 1 1 0 1 1 0 0 1 0 0 0 0 1 2 4 2 4 0 
7 839/16 62 1 2 0 2 0 3 2 1 1 0 0 3 2 1 3 1 2 0 
8 3027/16 70 1 1 0 1 1 3 1 1 0 0 0 0 1 2 4 2 4 0 
9 4191/16 64 1 3 0 1 1 1 0 1 0 0 0 0 1 2 4 2 4 0 
10 4478/16 78 1 1 0 1 0 0 0 0 0 0 0 0 1 2 4 2 4 0 
11 2308/16 79 1 3 20 2 1 1 0 0 1 1 1 6 3 0 0 0 0 1 
12 7040/16 67 1 1 0 1 1 0 1 1 0 0 0 0 1 2 4 2 4 0 
13 7100/16 70 1 1 0 1 2 1 1 0 0 0 0 0 1 2 4 2 4 0 
14 7310/16 65 1 3 0 1 3 0 0 1 0 0 0 0 1 2 4 2 4 0 
15 420/17 70 1 3 0 1 1 4 1 1 0 0 0 0 1 2 4 2 4 0 
16 551/16 83 1 1 80 3 0 0 0 1 2 3 3 2 3 0 0 0 0 0 
17 906/16 74 2 3 95 3 0 0 0 0 2 3 3 5 3 0 0 0 1 0 
18 1264/17 60 1 1 0 1 1 3 0 1 0 0 0 0 1 2 4 2 4 0 
19 4247/16 50 1 1 0 1 1 0 0 3 0 0 0 0 1 2 4 2 4 0 
20 2060/17 66 1 3 0 1 1 1 1 1 0 0 0 0 1 2 4 2 4 0 
21 1061/15 65 2 3 70 2 0 0 0 0 1 1 1 1 3 0 0 0 0 0 
22 864/16 72 2 3 50 2 0 0 0 1 1 1 1 2 3 0 1 0 1 0 
23 3785/17 86 1 1 0 1 1 1 0 0 0 0 0 0 1 2 4 2 4 0 
24 3292/17 68 1 1 0 1 3 1 0 1 0 0 0 0 1 2 4 2 4 0 
25 1263/17 94 2 3 90 3 0 0 0 0 2 2 2 1 3 0 0 0 0 0 
26 2163/17 67 1 1 0 1 1 0 1 1 0 0 0 0 1 2 4 2 4 0 
27 3554/17 60 1 3 0 1 1 2 0 0 0 0 0 0 1 2 4 2 4 0 
28 4379/17 60 1 1 0 1 1 1 0 1 0 0 0 0 1 2 4 2 4 0 
29 1555/17 78 2 3 80 4 0 0 0 0 2 5 5 1 3 0 0 0 0 0 
30 4529/17 73 1 1 0 1 1 0 1 1 0 0 0 0 1 2 4 2 4 0 
31 4668/17 57 1 1 0 1 1 0 1 1 0 0 0 0 1 2 4 2 4 0 
32 1178/17 77 2 3 70 3 0 0 0 0 2 2 2 5 3 0 0 0 1 0 
33 5405/17 73 1 1 0 1 3 1 1 1 0 0 0 0 1 2 4 2 4 0 
34 6028/17 67 1 3 0 1 1 1 2 1 0 0 0 0 1 2 4 2 4 0 
35 6458/17 70 1 1 0 1 1 0 1 1 0 0 0 0 1 2 4 2 4 0 
36 6976/17 70 1 1 0 1 3 0 0 1 0 0 0 0 1 2 4 2 4 0 
37 7193/17 55 1 3 0 1 1 1 1 3 0 0 0 0 1 2 4 2 4 0 
38 798/17 67 1 1 90 3 0 0 0 0 2 2 2 1 3 0 0 0 0 1 
39 1555/17 86 2 3 40 3 0 0 0 2 2 2 2 0 3 0 0 0 0 0 
40 7268/17 68 1 1 0 1 1 0 0 1 0 0 0 0 1 2 4 2 4 0 
41 347/17 83 2 3 80 4 0 0 0 0 2 4 5 1 3 0 0 0 0 0 
42 7481/17 72 1 3 0 1 3 2 1 3 0 0 0 0 1 2 4 2 4 0 
43 3631/17 72 1 3 50 4 0 2 0 0 2 5 5 1 3 0 0 0 0 1 
44 2693/17 65 1 2 0 1 1 1 1 1 0 0 0 0 1 2 4 2 4 0 
45 2700/17 64 1 1 0 1 1 1 0 1 0 0 0 0 1 2 4 2 4 0 
46 13/17 82 2 3 70 3 0 0 0 0 2 2 2 1 3 0 0 0 0 0 
47 2299/17 68 2 3 60 3 0 0 1 0 2 2 2 1 3 0 0 0 1 0 
48 3245/17 65 1 1 0 1 1 0 1 1 0 0 0 0 1 2 4 2 4 0 
49 6678/17 75 1 3 95 3 0 0 0 0 2 3 3 5 3 0 0 0 0 1 
50 2302/17 71 1 3 30 5 0 0 0 2,4 3 6 5 5 3 0 0 0 0 0 
  
